Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended:  04/22/15   
  
 
 
 
 
A Phase I/II Study of Temsir olimus + Week ly Paclita xel + Carboplatin for Re current or  
Metast atic Head and Neck  Squa mous Cell Cancer (HN SCC) 
 
MSKCC THERAP EUTIC/DIAG NOSTIC PR OTOCOL  
 
 
Principal  
Investig ator/Depart ment: David P fister, MD  Medi cine 
 
Co-Princi pal 
Investigator(s)/Depar tment: Han Xiao, MD  Medi cine- Basking Rid ge 
 
Investig ator(s)/Depar tment:  Eric Sher man, MD 
Alan Ho, MD 
Shrujal Ba xi, MD  
 
Sofia Haque, MD 
Hilda Sta mbuk, MD 
Eric Lis,  MD 
Sasan Kar imi, MD 
John Lyo, MD  
Vaios Hatz oglou, MD  
 
Ronald Ghossein, MD 
Marija Dro bnjak, MD 
Nora Katab i, MD 
Micha el Berger, MD  
 
Camelia S ima,  MD Medi cine 
Medi cine 
Medi cine 
 
Radiology 
Radiology 
Radiology 
Radiology 
Radiology 
Radiology  
 
Pathology 
Pathology 
Pathology 
Pathology  
 
Epi[INVESTIGATOR_128211]-Kettering Cancer Center  
[ADDRESS_144660]. N ew 
York, NY [ZIP_CODE]  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended:  04/22/15   
  
Ephraim  Casper, MD 
Audrey Ha milton, MD 
Mila Gorsk y, MD  
Sree Chala sani, MD 
Stefan Berger, MD 
Asma Lati f, MD 
Afsheen Iqbal, MD 
John Fiore,  MD 
Stuart Lichtman, MD 
Steven Sug arman, MD 
Avni Desai,  MD 
Julie Fa sano, MD 
Marisa Sie bel, MD 
Arlyn Apol lo, MD 
Pamela Dru llinsky, MD 
Zoe Goldbe rg, MD 
Kenneth Ng, MD  
Tiffany Troso -Sandoval,  MD 
Mich elle B oyar, MD  
Philip Caro n, MD, PhD 
Nancy Mi lls, MD  
Carolyn Wasserh eit-Leiblich, 
MD 
Stephanie Smith-Marr one, 
MD 
Micha el Fanucchi, MD  Medi cine – All Networ ks 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Mercy 
Medi cine – Mercy 
Medi cine – Mercy 
Medi cine – Mercy 
Medi cine – Mercy 
Medi cine – Phelps 
Medi cine – Phelps 
Medi cine – Phelps 
Medi cine – Phelps  
 
Medi cine – Phelps  
 
Medi cine – Phelps  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended:  04/22/15   
  
Consenting  
Profession al(s)/Depar tment:  David P fister, MD 
Eric Sher man, MD 
Alan Ho, MD 
Shrujal Ba xi, MD  
 
Ephraim  Casper, MD 
Sree Chala sani 
Martin Br ower, MD 
Audrey Ha milton, MD 
Mila Gorsk y, MD  
Han Xiao, MD 
Asma Lati f, MD 
Afsheen Iqbal, MD  
 
Stefan Berger, MD 
John Fiore,  MD 
Stuart Lichtman, MD 
Steven Sug arman, MD 
Julie Fa sano, MD 
Marisa Sie bel 
Avni Desai  
Arlyn Apol lo, MD 
Pamela Dru llinsky, MD 
Zoe Goldbe rg, MD 
Kenneth Ng, MD  
Tiffany Troso -Sandoval,  MD 
Mich elle B oyar, MD  
Philip Caro n, MD, PhD 
Nancy Mi lls, MD 
Carolyn Wasserh eit- 
Leibl ich, MD 
Stephanie Smith-Marr one, 
MD 
Micha el Fanucchi, MD  Medi cine 
Medi cine 
Medi cine 
Medi cine 
 
Medi cine – All Networ ks 
Medi cine – Baskign Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
Medi cine – Basking Ri dge 
 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Commack 
Medi cine – Mercy 
Medi cine – Mercy 
Medi cine – Mercy 
Medi cine – Mercy 
Medi cine – Mercy 
Medi cine – Phelps 
Medi cine – Phelps 
Medi cine – Phelps 
Medi cine – Phelps  
 
Medi cine – Phelps  
 
Medi cine – Phelps  
 
 
 
 
Please Not e: A Consenting Profes sional must have compl eted the ma ndatory H uman 
Subjects Education and Certi fication Program.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#:09 -131A(14)  
Amended:  04/16/ 14  
 
 
Table of Contents  
 
MSKCC THERAP EUTIC/DIAG NOSTIC PR OTOCOL ..............................................................  1 
1.0 PRO TOCOL SUMM ARY AND/OR SC HEMA................................................................  2 
1.1 SUMMA RY ............................................................................................................  2 
1.2 SCHEMA  ................................................................................................................  3 
2.0 OBJECTI VES A ND SCIENTIFIC AIM S..........................................................................  4 
2.1 PRIMARY  OBJECTI VES......................................................................................  4 
2.2 SECONDARY OBJECTIVE S............................. ...................................................  4 
3.0 BACKGROUND  AND RATIO NALE...............................................................................  4 
3.1 PALLIAT IVE C HEMOTH ERAPY FOR  RECURR ENT/METAST ATIC HN SCC 
............................................................................................................................. .... 4 
3.2 RATIO NALE FOR M TOR INHIB ITION IN HNSCC  ..........................................  5 
3.3 MTOR IN HIBITORS +  PLATIN UM/TAXA NE AG ENTS IN HN SCC ..............  6 
3.4 TEMSIRO LIMUS (TO RISEL®, CCI -779) ...........................................................  7 
3.5 RATIO NALE FOR  DOSE AND  SCHED ULE ......................................................  8 
3.6 RATIO NALE FOR TIS SUE C ORRELATE S........................................................  8 
4.0 OVERVIEW OF STUDY DESIGN/INT ERVE NTION  ...................................................  10 
4.1 DESIGN  ................................................................................... .............................  10 
4.2 INTERV ENTION  .................................................................................................  12 
5.0 THE RAPEUTIC/DIA GNOSTIC  AGENTS  .....................................................................  [ADDRESS_144661] AN............................................................... ....................................  17 
8.0 PRET REATMENT E VALU ATION ................................................................................  18 
8.1 REQUI RED DATA  ..............................................................................................  18 
9.0 TREATM ENT/INTE RVENTI ON PLAN  ........................................................................  [ADDRESS_144662] UDIES  .................................................................................  20 
10.0 EVA LUAT ION DURING TR EATMENT/INT ERVE NTION  ........................................  22 
11.0 TOXICITI ES/SIDE EF FECTS  .........................................................................................  23 
11.1 TOXICITY  MAN AGEMENT:  G ENER AL CONSIDE RATIONS  ....................  23 
11.2 HEMAT OLOGIC T OXICITY MA NAGEME NT ...............................................  24 
11.3 HEPATIC  TOXICITY  MAN AGEMENT  ............................................................  25 
11.4 MUCOSIT IS/STOMATITIS.................................................................................  27 
11.5 NAUSEA/ VOMITING  .........................................................................................  27 
11.6 DIAR RHEA ..........................................................................................................  28 
11.7 SENS ORY NEU ROPATHY  ................................................................................  29 
11.8 REN AL  TOXICITY  MAN AGEMENT  ..............................................................  30 
11.9 DERMA TOLOGIC TOXICIT Y..................................... ......................................  31 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended:  04/22/ 15  
  
11.10   HYP ERLIPI[INVESTIGATOR_128212]  .............................................................................................  31 
11.11   INTERSTI TIAL LU NG DISEASE (ILD )............................................................  32 
11.12  TO XICITIES NOT O THERWISE SP ECIFIED  ...................................................  34 
12.0 CRITERIA  FOR THERAPEUTIC  RESP ONSE/OUTCO ME ASSE SSMEN T...............  34 
13.0 CRITERIA  FOR REMOVAL FROM STUDY  ................................................................  36 
14.0 BIOSTATI STICS  .............................................................................................................  37 
14.1 PART 1 ( PHASE 1)  ..............................................................................................  37 
14.2 PART 2 ( PHASE II)  .............................................................................................  38 
14.3 ACCRUAL RATE  ................................................................................................  40 
15.0 RESE ARCH PA RTICIPANT  REGISTRATI ON AND RANDOMIZ ATION 
PRO CEDURES.............................................................................................................................  40 
15.1 RESE ARCH PA RTICIPANT  REGISTRATI ON.................................................  40 
 
16.0 DATA   MANAGEM ENT ISSUES  ..................................................................................  41 
16.1 QUALI TY ASSURANCE ....................................................................................  41 
16.2 DATA  AND SAF ETY MONITOR ING ...............................................................  41 
17.0 PROT ECTION OF HUMAN S UBJECTS  .......................................................................  42 
17.1 PRIVA CY .............................................................................................................  42 
17.2 SERIOUS  ADV ERSE EVENT ( SAE) REP ORTIN G..........................................  42 
17.3 RISKS, B ENEFITS, TOXICITIE S/SIDE EFF ECTS ......... ..................................  44 
17.4 ALTE RNATIVES/OP TIONS...............................................................................  44 
17.5 FINA NCIAL COS TS/BURD ENS........................................................................  44 
18.0 INFORM ED CONSENT PR OCEDURES  .......................................................................  45 
19.0 REFE RENCES .................................................................................................................  45 
20.0 APPE NDICES ..................................................................................................................  49 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 2 -  
  
1.0 PROTOCOL SUMM ARY AND/OR SCHE MA 
 
1.[ADDRESS_144663] received more than 2 p rior chemotherapy regi mens in the 
recurrent/metastatic disease se tting. 
 
In Part 1  (Phase I) of  the study, the primary endpoint is  to establish t he phase II recommended 
dose for the  combination of  temsirolimus + weekly pac litaxel + carbo platin.  Part 1 ( Phase I) 
features a  standard 3 + [ADDRESS_144664] udy.  Rules for dose es calation are pro vided in Se ction 4.1.1.  The dose 
of temsirolimus (the e xperimental drug) is  escalated at each  dose lev el, and the doses  of 
paclitaxel and carbop latin (the standard che motherapeu tic ag ents) are fixed.  The phase II 
recommended dose wi ll be the maximum dose level at wh ich <2/6 pa tients exper ience DLT.  
 
In view of  the ava ilable PK evidence  regar ding everolimus + paclitaxel [1], everoli mus + 
cisplatin [2], and the p lanned phase I  study te msirolimus + q 3 week pacl itaxel + car boplatin [3], 
PK studies are not planned in Pa rt 1 of this stud y. 
 
Note:  The dose esc alation plan was revised  in August 2010, and patie nts were enr olled 
on dose lev el 2 of the re vised pr otocol. 
 
Table 1:  P hase I Dose Levels (21 day cyc le) 
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel,  
Days 1 and 8  Carbopla tin 
Days 1 and 8  
1 N/A N/A N/A 
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.5  
 
In Part 2  (Phase I I) of the study, the primary endpoint is  to determine the objec tive response ra te 
(CR or PR) a fter two c ycles (appro ximately 6 weeks) of  treatment with the co mbination of 
temsirolimus + weekly paclitaxel + carbopl atin as palliative therapy for recurrent or  metastatic 
HNS CC.  A  two-stage design will  be employed.  
 
Radiologic  imaging of  evaluab le disease wi ll take place  after every 2 cy cles.  Pa tients may 
remain on study until progression of  disease or unaccep table toxicity. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 3 -  
  
1.2 Schema  
 
 
 
 
 
• Recurre nt/metastatic HNSCC  
• No more than 2 prior c ytotoxic  therapi[INVESTIGATOR_128213]/metastatic disease 
 
 
 
 
 
Pre-treatment eval uation and In formed Consent  
 
 
 
 
21 day cyc le 
Day 1:  Carbopla tin (C),  Paclitaxel (P), Te msirolimus (T) 
Day 8:  Carbopla tin (C),  Paclitaxel (P), Te msirolimus (T) 
Day 15:  re st 
 
 
 
 
Radiologic  imaging a fter every 2 cy cles (preferably CT or MRI)  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 4 -  
  
2.0 OBJECTI VES A ND SCIENTIF IC AIMS  
 
2.1 Primary  Objecti ves 
 
 
 
2.1.1  Part 1:  To establish the phase II  recommended  dose for the  combination of  temsirolimus 
+ weekly p aclitaxel + carbopl atin 
 
2.1.2  Part 2:  To determine the  objec tive response r ate (CR or PR) a fter two cyc les 
(approxi mately 6 weeks)  of treatment with the c ombination of temsirolimus + weekly 
paclitaxel + carbop latin as pa lliative therapy for recurrent or  metastatic HNSCC  
 
2.2 Secondary Objec tives 
 
2.2.1  To estab lish the sa fety of  temsirolimus + weekly paclitaxel + carbopl atin 
 
2.2.2  To esti mate median overall s urvival 
 
2.2.3  To identi fy poten tial molecu lar markers of  resistance to mTOR inhibi tion in tumor 
speci mens obtained  as part of  routine clinical care 
 
 
 
3.0 BACKG ROUND AND RATIONALE  
 
 
 
3.1 Palliative chemother apy for rec urrent /metastatic HNSCC  
 
Single age nt chemotherapy as pa lliative tr eatment typic ally achieves o bjective respon ses in 10 - 
30% of  patients.  Co mbination c hemotherapy  regimens appear to be a ssociated w ith increased 
response  rates and o ften with in creased toxi cities, but gene rally not  with i ncreased sur vival [4]. 
 
No c ombination che motherapy regimen appears to be supe rior to an other in terms of surviv al for 
patients wi th advanced  head and n eck canc er.  A Southwest Oncology  Group study  repor ted by 
[CONTACT_128229] 277 patie nts with advan ced head and  neck canc er to treatment with 
cisplatin plus 5-fluorou racil, carbo platin plus 5 -fluoroura cil, or methotrex tate monotherapy.   In 
the co mparision of  the doublet  regimens, cis platin plus 5 -fluoroura cil yielded a high er response 
rate than c arbopla tin plus 5-fluorou racil (32%  versus 21 %,  p = 0.05).  However,  median 
surviv al times were si milar in all three treatment groups in t he study [5].  Gibson rep orted a  
rando mized co mparison of  cispla tin plus 5 -fluorourac il (CF)  versus cisplatin plus pa clitaxel (CP) 
for 218 pati ents with ad vanced head  and neck c ancer.  Resp onse ra te (27% in CF gr oup, 26% in 
CP group) and  median surviv al (8.7  months in CF group, 8.1  months in  CP group) did not di ffer 
signicantly [6]. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/[ADDRESS_144665] t he epi[INVESTIGATOR_5169] r eceptor (EGFR), de monstrated an obje ctive 
respons re rate of 13% in  a phase II study of  [ADDRESS_144666] ory recurrent 
and/or metasta tic HNS CC [7].   Treat ment was gener ally we ll tolerated and the most co mmon 
adverse  event was rash.  In a phase  III study by  [CONTACT_128230] r eceived any p rior pa lliative chemotherapy, 117 sub jects we re randomized 
to cis platin plus c etuximab versus cisp latin plus placebo.  Objecti ve response r ate was higher for 
cisplatin plus cetu ximab (26% ve rsus 10%, p = 0 .03),  but t here was no s ignificant difference in 
surviv al between the t wo groups [8]. 
 
The addi tion of cetuxi mab to pl atinum-based che motherapy  was inves tigated further in a 
rando mized cli nical trial for 442 pati ents with u ntreated  recurrent or metastatic head a nd neck 
cancer [9].  Patie nts we re rando mized to cis platin (or c arboplatin, at  the disretion of  the 
inves tigator) plus 5 -fluorourac il in the contr ol group  versus t he cisplatin (or carbo platin)/5- 
fluoroura cil doublet plus weekly cet uximab in the experi mental group.  Objective response ra te 
(20% v. 3 6%, p < 0.0 01), progr ession-free sur vival (3.3 v. 5.6 months, p<0.001), and  overa ll 
surviv al (7.4  versus 10.1  months, p = 0.04) a ll favored the  experimental g roup.  Despi [INVESTIGATOR_128214] a the rapeutic option, o utcomes for patie nts with  recurrent or metasatic 
head and n eck canc er remain poor.  The median  surviv al in this group of  patients is typi[INVESTIGATOR_897] 10 
months or l ess. 
 
3.2 Rationale for mTOR inhibition in  HNSCC  
 
EGFR and other trans membrane rec eptors conv erge to con trol a var iety of  intracellular signa ling 
pathways, such as the phosphoinos itide-3-kinase (PI3K)/Akt /mammalian targ et of rapamycin 
(mTOR) pathway.   The i mportance of  the PI3K/Akt/ mTOR pathway in  HNS CC was 
demonstrat ed in a study  by [CONTACT_128231] T issue Array In itiative, which  evalu ated 
the this pat hway in a st udy of  547 pathology c ores, inclu ding contr ols, in  a tiss ue microarray 
(TMA) [10].  The TMA was inte rrogated with  antibodies directed ag ainst key sign aling 
molecules  in head and n eck canc er, including p53,  the epi [INVESTIGATOR_3506] (EGFR), 
and co mponents of  the Akt-mTOR pathway.  Alt erations of  the PI3K/Akt/ mTOR pathway were 
found in  most cas es.  As shown in Figure 1, pAKTSer473, pAKTThr308, and pS6 were s ignificantly 
higher  in HNSCC t umors, co mpared with nor mal mucosa, across all degrees of  differentiation. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 6 -  
  
 
 
Figure 1:  Distribution of immunoreacti vity segregated by d ifferentiation  groups. 
Diffe rences  in normal (N) tissue ve rsus well differentiated (W), moderately d ifferentiated 
(M), and p oorly d ifferentiated (P) tumors were s ignificant (*) for all proteins ex cept 
pEGFR  (NS) [10]. 
 
A key finding in this wo rk was that  the majority of head and neck canc ers appear  to have EGFR - 
independe nt activation of the PI3K/Akt/ mTOR pathway.  Within the c ollection of  HNSCC 
samples, an unsupervi sed clus tering  approach provided a clear sep aration of certain  clusters, and 
demonstrat ed that  the p athway o ften appeared  to be ac tivated  in the setting of negati ve staining 
for pEGFR  [10].  This suggests t hat activation of  the PI3K/Akt/ mTOR pathway  may occur 
independe ntly of  EGFR  activation in many head and neck c ancer p atients.  These findings may 
provide  insight into  the relatively low-to-modest cli nical efficacy of  EGFR inhibi tion strategies 
in this disease [11], and  suggest t hat downstream  inhibition of mTOR merits further study as a 
poten tial therapeu tic strategy in HNSCC.  
 
3.3 mTOR inhibitors + pl atinum /taxane agents in  HNSCC  
 
Rapa mycin, the pr ototypic mTOR inhibit or, de monstr ates modest a ntiproliferative e ffects a gainst 
HNS CC cell lines, w ith IC50s in the  range of  5 – 20 µM [12].  In HNSCC  xenogra fts, dramatic 
tumor growth inhib ition was achiev ed with te msirolimus [13] or rapa mycin [14]. Because it is 
probable  that mTOR inhibitors w ill have no be tter than modest c linical activity ag ainst HNSCC 
when given as sing le agents, the  true utility of  these agents may derive from their a bility to 
poten tiate the ant itumor effects of  other cyt otoxic chemotherapeut ic age nts. 
 
In 1995, Mi lls and cowo rkers rep orted that  rapamycin enhan ces the c ytotoxic e ffects of cispla tin 
again st a human leuk emia cell line (HL-60) and an ovar ian cancer cell line (SKOV3) [15]. 
Subsequent  pre-clinical studies demonstr ated additive or sy nergistic effects when mTOR 
inhibitors are combined with pl atinum or taxane  chemotherapy agents  in studies of  non-small 
cell lung ca ncer [16], breast ca ncer [17],  and  more rece ntly HNSCC cell l ines [12].   In the study 
of HNSCC cell lines, mTOR inhibiti on yielded  synergi stic effects when combined wi th 
carbop latin and pac litaxel [12]. The authors proposed th at mTOR inhibi tion may be  a strategy to 
decre ase resistance to p aclitaxel and carbop latin. Consiste nt with this, mTOR inhibi tion appe ars 
to rev erse resistance to paclitaxel in a  cervical cancer c ell line (CaSki) [18], and also a ppears to 
rever se resistance  to cis platin in lung  cancer  cell line (SCLC SR2) [19]. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/[ADDRESS_144667] re cently completed t he dose esc alation phase of  IRB 06 -129, “A Phase I s tudy of 
Weekly Low -Dose Cispla tin Plus Escalating D oses of  Oral RAD001 ( Everolimus) for Pat ients 
with Advanced Solid T umors.”   Par tial response  has been s een in pul monary c arcinoid (n=1) 
and HNS CC (n=1).  An other HNSCC patient  achieved a minor radio graphic respo nse, but was 
removed from study a fter expe riencing a pul monary e mbolus during cy cle 2 of  RAD001 + 
cisplatin.  Off study, the patie nt sub sequently  received an ad ditional 2 cy cles of  cisplatin alone 
with progr ession of  disease [2]. This phase  I experie nce su ggests t hat mTOR inhibi tors + 
platinum based che motherapy may achieve greater activity than would be seen with cisplatin 
alone, although no firm conclu sions can be dra wn from this s mall study.  The favorable sa fety 
profile of  the IRB 06 -129 regi men suggests t hat it should  be feasible  to add pacl itaxel to t he 
mTOR inhibitor + platinum backbone, which is an obvious r esearch direction to purs ue because 
paclitaxel has signi ficant palliative activity in HNSCC  [20]. 
 
3.4 Temsir olimus (Torise l®, CCI -779) 
 
Temsirolimus (Tori sel®, CCI -779)  and other  rapamycin analogues ( “rapalogues ”), such as 
evero limus and de forolimus, share the sa me mechanism  of action:  bind ing  to the  intracellular 
protein FK BP-12 to form a complex that in hibits mTOR signaling [21].  In phase I studies, 
temsirolimus de monstra ted encoura ging ac tivity again st renal cell carcinoma [22].   A phase II 
study rand omized 111 patients with  cytokin e-refractory metasta tic renal carcino ma to rec eive 
one of  three  doses of  temsirolimus, either 25, 75 or 250 mg intravenously  (IV) once w eekly. 
Median  time to progr ession was 5.8 months, which co mpared favorably to the ty pi[INVESTIGATOR_2855] 2.5 to 3.0 
months ti me to progr ession seen with  other  inves tigational  agents follow ing cytokine  therapy 
[23].  Given the si milar outcomes with the t hree doses of  temsirolimus, the lowest dose  of 25 
mgIV once weekly was chosen for the subsequ ent pi[INVESTIGATOR_128215] I II trial [24]. 
 
The pi[INVESTIGATOR_128216] I II trial included 626 previou sly untre ated patients wi th advanced renal ca ncer 
rando mized to one of  three ar ms; a control group receiving e scalating do ses of  alpha interferon 
alone, one  treatment arm  of 25 mg IV once weekly te msirolimus and another  treatment arm 
consis ting of a lower dose of  temsirolimus (15 mg) IV once weekly co mbined with  interferon 
alpha 6 MU  subcutaneo usly th ree times per week  [24].  The overall survival was sig nificantly 
greater in the temsirolimus group ( median v alue 10.9 months) co mpared with the  interferon 
monothera py group ( median val ue 7.3 months).  The overa ll surviv al of patients receiving the 
combination of  temsirolimus and int erferon was not gre ater than that of  patients receiving 
interferon a lone.   Among the gra de [ADDRESS_144668] co mmon. 
Temsirolimus was also  associ ated with a v ariety of laborat ory ano malies, inclu ding anemia, 
hypergly cemia, hyperl ipi[INVESTIGATOR_128217].  In 2007, te msirolimus received FDA 
approval for use in p atients with ad vanced kidn ey car cinoma. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 8 -  
  
3.5 Rationale for Dose and Schedule  
 
We feel that  the appro priate follow -up clinical trial is a phase  I/II study of  temsirolimus + weekly 
paclitaxel + carbop latin. Studies in other tumor types suggest  that p aclitaxel on a we ekly 
schedule has a more favorable  toxicity pro file than q 3 week pacl itaxel [25] [26].   The  weekly 
paclitaxel schedule p airs well with weekly temsirolimus a dministration.  Weekly eve rolimus 
was well t olerated when co mbined with weekly paclitaxel in a  phase I study, and  no significant 
pharmacokinetic  interaction b etween the mTOR inhibitor a nd pacl itaxel was iden tified [1].   The 
regimen of  carbopl atin (day 1) and paclitaxel (days 1, 8, and 15) on a 28 -day schedu le has 
excellent activity as  in duction c hemotherapy for patients wi th loca l-regionally ad vanced 
HNS CC [27].  In the cu rrent study, we propose  somewhat l ower doses of  carbop latin and 
paclitaxel in the pa lliative-intent setting for pre -treated p atients.  The reg imen in this proposal,  if 
it shows si gnificant activity in  this study, would be at tractive for further study as an  induction 
chemotherapy regi men in HNS CC because  the carbopl atin-based re gimen may be bett er 
tolerated  than the widel y-used c isplatin-based  induction c hemotherapy  regimens [28-30]. 
 
The dose e scalation sc heme select ed for this st udy builds u pon the phase  I expe rience repo rted 
by [CONTACT_128232]  [31], in wh ich te msirolimus (25  mg intravenous ly, day 1 and day 8) was  well 
tolerated w hen co mbined with pac litaxel (175 mg/m2, day 1) + carbo platin (AUC 5, day 1) on a  
21 day cycl e.  However, when te msirolimus was  given on Days 8 and 15 (co mbined with 
paclitaxel 175 mg/m2 and carbop latin AUC 5 on  day 1 of  a 21 day cycl e), treatment was not 
feasible due  to myelosuppression.  
 
The curre nt study features a [ADDRESS_144669] che motherapy, 3 do se levels of 
temsirolimus (15 mg, 20  mg, and 25 mg) are pla nned.  The doses of  the standard 
chemotherapeutic  agents (carbo platin, pacl itaxel) are fixed. Dose esca lation beyond 
temsirolimus 25 mg weekly is not  planned beca use this  is the FDA -approved dose for this a gent 
in advanced  renal  cell cancer [24]. 
 
3.[ADDRESS_144670] on the genet ics of  the tu mor [32-33]. 
Accordingl y, Secondary  Aim 2.2.4 of the pr otocol is “To ide ntify potent ial molecular markers of 
resistance to mTOR inhibition  in tumor speci mens obt ained as part of  routine clinical care.”  The 
intent of this secondary  aim is to col lect p ilot data that may guide the development of a new 
HNS CC research program in [CONTACT_128259]’s  lab. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 9 -  
  
Our working hypothesis  is that HNSCC t umors with cons titutive activation of  the Akt/ mTOR 
pathway (i .e. due PI3K mutation or  PTEN loss) will be associated with responsiven ess to 
temsirolimus-based  treatment, and HNSCC t umors with lesions that  act downstream  of mTOR 
(ie, eIF4E) or disa ble ap optosis  (bcl-2 or loss of  p53) will be associ ated w ith resistance to 
temsirolimus-based  treatment. 
 
HNS CC is a genet ically hetero geneous disea se and we have asse mbled a panel of  cell lines that 
repre sents this he teroge neity.   Spe cifically, we will study c ell lines w ith known  mutational 
activation of  the Akt -mTOR signali ng pathway, such as Detr oit 562 c ells, which harb or a 
PIK3CA  mutation [34], RPMI 2650 cel ls that activate mTOR  via a LKB1 exon 5 missense 
mutation [35], the FaDu line  lacks PTEN [36]. We will also  include  cell lines harboring 
mutations  in apopto tic regulators, su ch as SCC-15, which is p 53 mutant a nd express es high 
levels of Bcl2 [37]. Lines like CAL27 [38], SCC-25 [39] are less we ll characterized and will be 
examined here. Fin ally, while A549 cel ls are n ot primarily HNSCC, but a  patholo gically si milar 
lung canc er line, this line is esp ecially interesting as it maintains an i ntact mTOR-mediated 
feedback si gnal th at has  been rep orted to count er the c ellular effects of mTOR inhibi tion [40]. 
Thus, these  cell lines represent  the major types of  genet ic lesions seen in  HNS CC. 
 
We will ana lyze the se HNSCC lines for markers  that ha ve been implicat ed in rapa mycin 
(temsirolimus) respo nses. Brie fly, we will u se established a ssays (i mmunoblot, ex pression and 
sequence a nalyse s) to p robe mTOR activation, parallel and downstream  signa ling pa thways, and 
regul ators of  cell death.  These ce ll lines will  also provide us  with an op portun ity to evalua te 
response p atterns  to temsirolimus in a panel of  HNSCC lines, and to ide ntify associ ations with 
marker expression as determined above.  Ulti mately, th ese in vitro studies will in form our 
interpretation of data ob tained from clinical s pecimens. 
 
The propos ed tissue  correlative studies, which a re desc ribed in Section 9 .2 of this pr otocol, b uild 
largely on p revious in vestigations of  PI3K/Akt/ mTOR signal ing in oth er tumor types  by [INVESTIGATOR_124]. 
Wendel.  Key observa tions from this body of  work include  the following:  
 
1)   There is dramatic syne rgy of mTOR inhibition with che motherape utics in vivo [33, 41 ]. 
2)   This effect was strictly dependent  on the tumor genoty pe, e.g. PTEN,  Akt, Rheb  and 
TSC2 were positi ve and  Bcl2 nega tive pred ictors [42]. 
3)   The  eIF4E  trans lation  factor  is  an  oncogene  in  vivo  and  can  block  respon ses  to 
rapamycin [33 ]. Of note: eIF4E is  an independe nt pre dictor of outco me in HNS CC [43]. 
4)   eIF4E functions in can cer requ ire the eIF4E kina se MNK [44-45]. 
5)   Direct mTOR activ ation by [CONTACT_128233]  [46]. 
6)   Tumors that expre ss Rheb  are particularly sensitive to rapamycin (temsirolimus) and that 
inhibitors of  farnesyl transferase d irect block Rheb  activity [47]. 
7)   Apoptotic  regulators including  p53 or Bim, and also parallel kinase  pathways  (e.g. Pim 
kinase s) can  affect rap amycin (te msirolimus) ac tivity in vivo  [42, 48 ]. 
8)   Levels  of the anti-apoptotic Mcl1 protein  are regulated  by [CONTACT_128234]4E.  Moreover, 
Mcl1 can block the t herapeut ic effect of  mTOR  inhibition [46, 49 ]. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/[ADDRESS_144671] UDY DESIGN/INT ERVENTION  
 
4.1 Design  
 
This will be an open -label non -randomized phase I/II study open at MSKCC and reg ional 
network a ffiliates. 
 
 
 
4.1.1  Part I  (Phase  I) 
 
Part 1 (ph ase I) features three planned dose lev els. 
 
Note:  The dose esc alation plan was revised  in August 2010, and patie nts were enr olled 
on dose lev el 2 of  the re vised protocol. 
 
Table 1:  P hase I Dose Levels (21 day cyc le) 
 
Dose Level  Temsirolimus, 
Days 1 and 8  Paclitaxel,  
Days 1 and 8  Carbopla tin 
Days 1 and 8  
1 (starting dose) N/A N/A N/A 
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.5  
 
Cycle len gth is 21 days.  If 0/3 pat ients expe rience DLT dur ing Cycle 1 at a given d ose level, 3 
patients wi ll entered at  the next hig her dose level.  If 1/3 pat ients exp erienced DLT during Cycle  
1, 3 addi tional pa tients will be ent ered at t his do se level (for a total of 6). 
 
If none of  these add itional [ADDRESS_144672] one  of the addi tional pa tients exper ience DLT during 
Cycle 1, the  MTD is ex ceeded.  
 
If the MTD is exc eeded at a dose  level, pa tients may be enrolled at the next lower d ose lev el. 
This lower dose at which  patients tolerate the co mbination would then b ecome the ph ase II 
recommended dose if  no more than  1/6 pa tients exper ience a  DLT during Cycle 1.  
 
There wi ll be no esc alation beyond Level 3.  If  0/3 or 1/3 p atients exp erience dose -limiting 
toxicity at Level 3, t his dose lev el will be expand ed to 6 pa tients.  If  no more than 1/6 patients 
exper ience DLT at Level 3, t his will be the p hase II recommended dose.  
 
Adverse events (AEs)  will be assessed accor ding to NCI common t oxicity criteria (CTC) 
version 3.0.  Dose Li miting Toxic ity (DLT) incl ude all  toxicities of grade  3 or highe r, with 
the excep tion of those listed belo w: 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 11 -  
  
The following will not be consid ered to be DLT:  
● Grade 3 dy sphagia an d/or grade 3 odynophagia  (pain)  (even  if PEG tube is 
requi red), if the inv estigator’s impression is  that dysphagi a/odynophagia is due to 
head and n eck canc er 
● Grade 3 or 4  lymphopenia  
● Grade 3 fatigue 
● Grade 3 ac neiform rash 
● Grade 3 hyp omagnese mia 
● Grade 3 di arrhea lasting ≤  48 hours  
● Grade 3 na usea and/ or grade 3 vo miting la sting ≤  72 hours  
● Uncomplicated Grade 3  or 4 neutro penia lasting ≤ 7 days  
● Grade 3 thr ombocytopenia  
● Grade 3 low he moglobin, even if  treatment is gi ven with s timulators of 
erythrop oiesis or pack  red blood ce ll trans fusions  
● Non-infectious pneu monitis, because this is an u ncommon te msirolimus-related 
toxicity that is not strictly related to  the dose le vels in t his study 
● Deep vein t hrombosis  or pul monary e mbolus, be cause such e vents a re common in 
patients wi th cancer  and are not strictly related to  chemotherapy dose  
● Hypersens itivity reaction to any of  the study dru gs regar dless of grade, b ecause 
such events  are not strictly dose -related. 
● Grade 3 hypergly cemia 
● Uncomplicated Grade 4  hypergly cemia for ≤ 24  hours  
● Grade 3 hypercho lesterolemia 
● Uncomplicated Grade 4  hypercho lesterole mia for  ≤ 7 days  
● Grade 3 hypert riglyceridemia 
● Uncomplicated Grade 4  hypercho lesterole mia for  ≤ 7 days  
● Grade 3 hypokale mia 
● Grade 3 hypocalce mia 
● Grade 3 hypophosphat emia 
● Grade 3 le ukopenia  
 
 
 
4.1.2  Part 2 (Pha se II) 
 
Part 2 (Pha se II) of  the study will o pen after the phase II  recommended  dose is e stablished  in Pa rt 
1.  In Part  II, all patients will be  treated at t he phase II recommended do se. 
 
In the first stage of  this design, [ADDRESS_144673] a response a fter 
2 cycles of  treatment out  of a total of  36 patie nts enrolled, the  regimen will be con sidered worthy 
of further i nvestigation.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 12 -  
  
4.2 Interven tion 
 
In Part 1, on  Cycle 1/D ay 1 patie nts receive pa clitaxel (P), c arbopl atin (C), and te msirolimus (T) 
intravenous ly on Days 1 and 8 of  each cycle, according t he dose lev el plan.  The sequence of 
administra tion will be P→C→T, in view of  preclinical d ata that ad ministration of mTOR 
inhibitor prior to pa clitaxel is subo ptimal in HN  cell lines [12].  Cycle 1/Day [ADDRESS_144674] week  at the end of  Cycle 2, p atients undergo  response assessment imaging (CT a nd/or MRI) 
of sites of  measura ble disease.  Pa tients may remain on study  until time of progressi on of disease 
and/or un accepta ble toxicity. 
 
In view of  the ava ilable PK evidence  regar ding everolimus + paclitaxel [1], everoli mus + 
cisplatin [2], and the p lanned phase I  study te msirolimus + q 3 week pacl itaxel + car boplatin [3], 
PK studies are not planned in Pa rt 1 of this stud y. 
 
In Part 2, of  the study, patients are treated a ccording to  sched ule used  in Part 1, at the phase II 
recommended dose es tablished  in Part 1.  Adve rse event manage ment guide lines, i ncluding do se 
reduc tions for tox icity, will be provided in Sec tion 11 of  this protoc ol document. 
  
 
5.0 THERA PEUTIC/DI AGNOSTIC AGENTS  
 
5.1 Temsir olimus 
 
Availab ility 
 
Temsirolimus is pro vided by P fizer in kits co ntaining 25 mg/mL temsirolimus plus a 1.8 
mL diluent  vial. 
 
Storage and  Stabi lity 
 
Temsirolimus should be  stored at refrigerated temperature  (2 – 8  C).  Do not freeze. 
Prote ct vials from light. Reconst ituted vials  are stable for [ADDRESS_144675] 1.8 mL of the dilu ent into  the v ial 
of temsirolimus injec tion.  The te msirolimus vial contai ns an overfill of  0.2 mL (30 
mg/1.2  mL).  There fore, addition of  the dilue nt yields a co ncentration of  10 mg/mL, with 
a total volume of 3 mL.  Mix well by [CONTACT_128235].  Allow su fficient  time for air 
bubbles to subside.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 13 -  
  
Do not use PVC in fusion bags or in fusion se ts. Add the cal culated d ose to 250  mL NS. 
Dispense in fusions in a mber bag.  Pr emedication with diphe nhydra mine 25 – 50 mg IV 
should be g iven to pre vent/reduce t he seve rity of  reactions, at the di scretion of  the 
inves tigator. Administer  temsirolimus as an IV i nfusion over  approxi mately 30 minutes.  
 
 
 
Toxic ities 
 
Metab olic: hypergly cemia, hyperl ipi[INVESTIGATOR_035], hypert riglyceridemia, hyp ophosphate mia, 
hypokale mia 
 
Hematolog ic:  ane mia, thrombocytopenia, leukopenia, ly mphopenia 
Gastroi ntestinal:  mucositis, an orexia, nausea, v omiting, diar rhea 
Renal:  elevated s erum creatinine,  renal failure 
Hepati c:  elevated liver function  tests 
 
Pulmonary:  dyspnea, c ough, int erstitial lung dis ease (ILD) 
Reproducti ve:  possi ble infertility; may be t eratogen 
Misc ellaneous:  fatigue,  asthe nia, moderate-severe hypersen sitivity reactions, abnor mal 
wound heal ing, rash, ed ema, headache, te mporary  muscle and  joint aches/pains 
 
5.2 Paclita xel 
 
Availab ility 
 
Paclitaxel is commercia lly supplied  as a non -aqueous solu tion intended for dilution wi th 
suitable parenteral fluid prior to intravenous in fusion.  Pac litaxel is  available as 30 mg 
(5ml), 100 mg (16.7  ml) and 300 mg (50 ml) multiuse vials. 
 
Storage and  Stabi lity 
 
Unopened vials of  paclitaxel are stable until the date in dicated on the pac kage when 
stored b etween 20 – [ADDRESS_144676].  U pon re frigeration, co mponents of  the 
paclitaxel vial may prec ipi[INVESTIGATOR_047], but will re-dissolve upon reac hing room  temperature with 
little or no agitation. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 14 -  
  
Preparation  and Administra tion 
 
Prior to  infusion pa clitaxel should be diluted in 0 .9% Sodium  Chloride  injection or 5% 
Dextrose i njection or 5%  Dextrose a nd 0.9% Sod ium Chloride  or 5% Dex trose in Rin gers 
Lacta te to a  final conce ntration of  0.3 to 1.2 mg/mL.  Paclit axel must be prepa red in  
glass, poly propylene or polyole fin containers and  non-PVC contai ning in fusion se ts. 
Prepared s olutions are stable at room  temperature  (20-25 C) and prote cted from light, up 
to 72 hours.  In-line filtration with micropore no greater than 0.22 micron filter is 
requi red.  Che mo dispensing pin de vices or  similar dev ices should not be  used with 
paclitaxel vials si nce they can cause  the stop per to colla pse resulting  in loss of  sterile 
integrity 
 
Safety P recautions – Paclitaxel 
 
Paclitaxel does not co ntain an timicrobial s; therefore, extre me care must be taken  to 
ensure sterility of  the p repared s olution. 
 
Subjects sh ould be pr e-medicated to  reduce risk of severe hy persen sitivity reaction. 
Decadron p re-medicati on prior  to paclitaxel w ill follow inst itution al gui delines, and  may 
be tap ered at  the di scretion of  the in vestigator. 
 
Toxic ities 
 
Hematolog ic:  neu tropenia, leuko penia, t hrombocytopen ia, anemia 
 
Gastroi ntestinal:  na usea/vomiting, d iarrhea, mucositis 
 
Hepati c:  elevated liver function  tests 
 
Cardia c:  heart block, b radycar dia 
 
Neurologi c: periph eral neuropathy,  arthralgia/myalgia 
 
Dermatologic:  alo pecia, onycholysis  
 
Reproducti ve:  In fertility; may be teratogen  
 
Misc ellaneous:  moderate – severe hypersen sitivity re actions, flushing, r ash, dyspnea, 
fatigue  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/[ADDRESS_144677] atin c oncent ration of 10 mg/ml. 
 
Administr ation 
 
IV in fusion over [ADDRESS_144678] with it and c ause pote ntial 
loss of potency.  Anti -emetics gene rally will follow instit utional guid elines, but may be 
altered at the disc retion of the inves tigator. 
 
Toxic ities 
 
Hematolog ic:  leuko penia, ane mia, thrombocytopenia  
 
Gastroi ntestinal: an orexia, nausea, vomiting, hy perbilirubinemia, elevat ed liver enz ymes. 
Renal:  rarely, alt erations in ren al function are seen. 
Neurosenso ry:  sensory neuropathy,  tinnitus, h igh frequency hearing  loss 
 
Reproducti ve:  In fertility; may be teratogen  
 
Misc ellaneous:  r arely, severe allergic rea ction; hair thinning  and hair  loss 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/[ADDRESS_144679] microscopic ally confirmed head and neck  squamous cell carcinoma 
(HNSCC), recurrent an d/or metasta tic. 
 
Note: Con firmation of  HNSCC  may be obtai ned from the pr imary site or  metastatic 
disease.  
 
6.1.[ADDRESS_144680] be ≥ 70%.  
 
6.1.[ADDRESS_144681] 
recov ered from the acute  toxic e ffects of treatment pri or to study enro llment. 
 
6.1.6  Adequate o rgan functio n, as follows:  
Adequate b one marrow reserv e:  absolute ne utrophil cou nt (ANC) ≥  1.5 X 109/L, 
platelets ≥ 100 X 109/L, and he moglobin ≥ 9 g/ dL. 
 
Hepati c:  total bilirubin within nor mal limits (≤  1.0 mg/dL);  alkaline ph osphatase 
(AP), aspa rtate transa minase (AST)  and ala nine transa minase  (ALT) ≤ 1.[ADDRESS_144682]  (upper li mit of normal) 
 
Renal:  Ser um creati nine ≤ 1.3 mg/dL.  Patien ts with serum  creatinine > 1.3 
mg/dL may be eli gible if creatinine clearance (C rCl) ≥ 45 mL/min based on the 
standard C ockroft and Gault formula. 
 
6.1.[ADDRESS_144683] Exclusion Criteria 
 
6.2.1  Previous e xposure to  temsirolimus or other mTOR inhibito rs 
 
6.2.2  More than 2  prior c ytotoxic re gimens in the  recurrent/metastatic disease setting 
 
6.2.3  History of  any brain metastas es 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 17 -  
  
6.2.4  Patie nts who requi re concomitant medications that are metabolized by [CONTACT_128236]3A4, 
due to pote ntial drug -drug interaction with te msirolimus (prohibi ted medication  list 
provided  in Appendix A.)  
 
6.2.5  Patie nts with known active i nterstitial pneu monitis  
 
6.2.6  Active in fection or serious underl ying medical c ondition  that would i mpair the p atient’s 
ability to  receive pr otocol treatment. 
 
6.2.7  Women who are p regnant or lactating 
 
6.2.8  Other a ctive malignanc y, other  than indolent malignancies w hich the  investigator 
deter mines are un likely to interfere with treatment and sa fety analysis  
 
6.2.9  Diagnosis of  Nasophary ngeal ca ncer is excluded.  
 
6.2.9  Patie nts with multifocal periph eral sensory a lterations or paresthe sias (including  tingling) 
interfering  with function, per pa tient repo rt (example: ac tivities of  daily living)  
 
6.2.10  Therapeu tic anticoagulation with C oumadin (wa rfarin) 
 
6.2.11  Hypertri glyceride mia  ≥  grade 2 (C TCAE version 3.0).  
 
6.2.12  I mpaired l ung function:  O2 satura tion 88% or l ess at r est on room air by  [CONTACT_128237]. 
If O2 satura tion is ≤ 8 8% at rest, further pul monary function t ests (PFTs) should be 
ordered  to confirm normal pul monary function and eli gibility. 
 
7.0 RECRUITMENT PLAN 
 
Potent ial research su bjects will be identified by a member of the pa tient’s treatment team, the 
protoc ol investigator, or research team at Me morial Sl oan-Kettering Can cer Cent er (MSKCC). 
Patie nt recruitment will occur in medical onc ology clinics of  the Head and  Neck Dise ase 
management team  at main ca mpus a nd in medical oncology c linics of  MSKCC regional network 
sites.  If the inves tigator is a member of the treatment te am, s/he wi ll screen the ir patient’s 
medical re cords for sui table research study pa rticipan ts and  discuss  the study and th eir potential 
for enrol ling in the  research study.  Potential su bjects co ntacted by [CONTACT_128238] w ill 
be re ferred to the inv estigator/research sta ff of the study.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/[ADDRESS_144684] con firm diagnosis of  HNSCC prior to  treatment. 
Confirmation of  HNSCC may be obtained from the p rimary site or metasta tic disease.  
 
8.1.4  The following labor atory studies w ill be obt ained within 21  days pri or to therap y: 
Complete b lood count with whi te blood cell differential and platelet counts; 
Comprehensive pro file (including electrolytes, bicarbon ate, blood urea nitrogen (BUN), 
creatinine, glucose, alkaline phosph atase, asp artate aminotrans ferase (A ST), ala nine 
aminotrans ferase  (ALT), tot al bilirubin, to tal protein, albumin, and glu cose);  lipid panel; 
prothro mbin ti me and activ ated pa rtial thromboplastin time. 
 
8.1.[ADDRESS_144685] for women of childb earing  poten tial w ithin 14 days  prior to 
therapy.  
 
8.1.6  Electrocar diogram  within 8 weeks p rior to  therapy 
 
8.1.7  Radiologic  imaging of  neck (p referably, CT scan  or MRI), c hest (preferably, CT scan ), 
and any oth er sites of  measurea ble disease wi ll be obtained w ithin [ADDRESS_144686]  (with or without  contra st). 
 
9.0 TREATM ENT/INT ERVENTION PLAN  
 
9.[ADDRESS_144687].  
 
9.1.2  To faciliate the timely ad ministration  of chemotherapy on t reatment days, CBC and BMP 
with magnesium  level  may be obt ained 1 calen dar day pri or the che motherapy t reatment 
date, if  need be.  For Day 1 of  each cycle, liver Function Te sts and Lipid  Panel may be 
obtained w ithin 7 ca lendar days p rior to the c hemotherapy  treatment date,  if need be.  For 
Cycle 1 onl y,  Liver Fu nction Te sts and Lipid P anel are opti onal if  previously obt ained 
within 14 d ays prior.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 19 -  
  
9.1.3  On (or be fore, See Sec tion 9.1.2) Day 1 of  each cycle, co mplete blood co unt and ba sic 
metabolic panel with magnesium  level, liver function  tests, and li pid panel wi ll be 
checked.  
 
Note in c larificatio n: Lipid panel  results are not necess ary to clear a patient for treatment. 
 
9.1.4  Patie nts will be exa mined on Day 1 of  each cyc le.  During Cycle 1 of  the Phase I po rtion 
of the study  patients wi ll be evalu ated for each weekly treatment in clinic by  [CONTACT_128239]/or nu rse.  After  Cycle  1 in Pha se 1, the req uirement will be one MD c linic visit per 
cycle, w ith additio nal clinic vi sits scheduled as needed.  In Phase II of  the study, ag ain 
the req uirement wi ll be one MD cli nic vis it per  cycle, with  additio nal clinic vi sits 
scheduled  as needed.  
 
9.1.5  On Day 1 and Day 8 of  each Cycle, patients receive pac litaxel (P), carbo platin (C), and 
temsirolimus (T) i ntravenously acc ording the do se level plan.  The seque nce of 
administra tion will be P→C→T.  
 
 
Carbopla tin dose isc alculated accor ding to the Cockcro ft and  Gault M ethod.  For Cycle  
1/Day 1 dose, the in vestigator (at his/her dis cretion) may use eith er (a) the serum 
creatinine and body weight measure ments obtained on Cyc le 1/Day 1, or (b)  the most 
recent serum creati nine and body weight measure ments pri or to Cycle 1/Day 1, if  this 
was obtain ed within 21  days pri or to therapy.  
For overwe ight pa tients (body mass index ≥ 27),  adjus ted bo dy weight is  allowed for the 
calculation of carbopla tin and pac litaxel dosing  in this pr otocol [50], but is  not mandatory, at  the 
discretion of  the inv estigator. 
 
The study will  adhere  to recent FDA  guide lines regarding  cappi[INVESTIGATOR_128218] 
(http://www.hematology.org/News /?filter_Id=335).  Speci fically, the FDA reco mmends cappi[INVESTIGATOR_128219] ( AUC) to avo id poten tial toxicity due to 
overdosing.  Based on t he Calve rt formula desc ribed in the  carbopl atin label, the maximum doses 
were ca lculated as follows in the recent FDA  memorandum  regarding  carbopla tin do sing: 
Total Carb oplatin Dose  (mg) = (tar get AUC) x (GFR +25)  [Calvert formula] 
 
Maxi mum Carbopl atin Dose (mg) = target AUC ( mg•min/mL) x (150 
mL/min) 
 
The maximum dose is b ased on a GFR esti mate that is  capped at 125 mL/min 
for patie nts with nor mal renal function.  No higher es timated GFR values  
should be u sed. 
 
For a tar get AUC = 1.5,  the maximum dose is 1.5 x 150 = 225  mg 
For a tar get AUC = 1, t he maximum dose is 1 x 150 = 150 mg 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/[ADDRESS_144688] atin dose redu ction is n ot required at the completion of  a cycle, the inve stigator 
may use the sa me “flat dose” of  carboplatin for the next cy cle.  Alter natively, at his/her 
discretion, the inve stigator may re -calculate the dose of  carboplatin for Day [ADDRESS_144689] s cans and/or  MRI scans  will be p erformed to evaluate a p articular lesion. 
Addition al imaging  may be obtai ned as clinically indicated. Dermal les ions may be 
evalu ated by  [CONTACT_128240], suppl emented by p hotographs.  
 
 
Radiologic  response as sessment typi [INVESTIGATOR_897] w ill take place d uring the “b reak week” of  each 
even-numbered cy cle.  For pa tients who develop int ercurrent medical proble ms or 
logistical issues, respon se assess ment and study  treatment may be delayed  at the 
discretion of  the treating physic ian. 
 
9.1.[ADDRESS_144690], or inve stigator judg ment. 
 
9.1.10  At any ti me after 6 cy cles of study t reatment, pa tients who maintain stable disea se (or 
better) have the option of remaining on tre atment with te msirolimus alone.  The 
temsirolimus dose and schedule wo uld be uncha nged (2 wee ks on, 1 week o ff). 
However, a cli nic visit with lab oratory stud ies would only be requ ired on week 1 of  each 
cycle for patients who o pt to receive temsirolimus alone.  Re sponse asse ssment interv al 
typi[INVESTIGATOR_897] w ould re main q 2 cycles.  (For pa tients who re main on study be yond the i maging 
assess ment at the  end of  cycle 6,  the interval of  subsequent response ass essment imaging 
studies may be inc reased  to q3 cyc les, at inv estigator di scretion.)   For any  patient who 
opts to receive te msirolimus alone a fter 6 c ycles, the reasons for the  treatment change  
will be doc umented in a cli nic note.  
 
 
Altern atively, patie nts may continue to r eceive  temsirolimus + carbo platin + p aclitaxel, 
per prot ocol, after co mpletion of  6 cycles of  treatment.  If  a patient opts  to rec eive 
temsirolimus alone, h e/she will n ot be allowed  to receive add itional carb oplatin + 
paclitaxel on the study.  
 
9.2 Correla tive Studies  
 
Secondary  Aim 2.2.4 of the pr otocol is “To ide ntify potent ial molecular markers of  resistance to 
mTOR inhibition  in tumor speci mens obtai ned as part of  routine clinical care.”  We expect to 
collect ap proximately 30 HNS CC tissue para ffin-embedded speci mens from  patients  enrolled in 
the c linical study.  No r esearch biopsies a re plan ned in the  course of  the study.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 21 -  
  
Tissue co rrelates will be performed on biopsy or  surgic al pathology material that was  obtained  as 
part of  routine care  at time of diagnosis or at any point in  the management of  the pa tients 
HNS CC.  Tumor tissue  from the pr imary site or  from a metasta tic depo sit would be considered  
to be acceptable for pu rposes of  the study.  
 
To chara cterize the expr ession pa tterns of biomarkers, conve ntional i mmunohistoc hemistry (IHC)  
or tissue microar ray (TMA) analysis w ill be per formed.  [CONTACT_128259]’s group has used the sa me 
TMA  analyses  in hematopoietic can cers before and is  exper ienced  with the  techniques and the 
antibody  and st aining parameters  [51-52].  In the Core Fac ility of  the Depart ment of Pathology,  
Dr. M. Drobnjak wi ll supervise  tissue TMA constru ction from all pa tient samples (typ ically, 
paraffin sec tions approx imately 5 µm thick)  as p reviously described [51-55].  No rmal squa mous 
epi[INVESTIGATOR_128220] e ach array.  For biop sies where material is  
inadequate for TMA constru ction, immunohisto chemistry wi ll be per formed on whole mount 
tissue  sections in stead.  
 
We have es tablished po sitive and n egative  controls for each  antibody  to ensure c orrect 
interpretation of stains [51-52].   Antibodies to be used in TMA inte rrogation include:  total and 
phosphoryl ated eIF4E (Cell Sign aling, #9742 and  #2215);  total and p hosphoryl ated 4E -BP1 
(Cell Sig naling, #9644 and #2855), total and ph osphoryl ated (Ser 473) Akt (1:100 0; Cell 
Signaling # 9272, #9271);  total and p hosphoryl ated (Ser240/ 244) riboso mal S6 (1:10 00; Cell 
Signaling, #2317, #2215); p53 ( 1:500; Novocas tra, NCL -p530505); p21 (1:1000, San ta Cruz 
Biotechnol ogies, c -19); Rheb (1:10 00; Cell Sig naling, #493 5); MCL1 (1 :1000, Santa  Cruz 
Biotechnol ogies, S -19); Actin ( 1:5000; Sig ma, AC-15); and anti-HA (1: 5000, [COMPANY_002],  
#12013819).  
 
If sufficient  tissue  is available, we w ill also  per form genomic analy sis. DNA will be extr acted 
from FFPE surgic al pathology sa mples. We will perform the MSK -IMPACT assay (I ntegrated 
Muta tion P rofiling of  Actiona ble Cancer Tar gets), as follow s. Barcoded sequence libraries w ill 
be prep ared (Kapa Bios ystems, New  England Bi olabs) according to a modified prot ocol. We will 
perform exon captu re on barcoded pools of  libraries by [CONTACT_128241] (N imblegen EZ SeqCap) 
using cust om oligonuc leotid es to capture all exons and sel ect introns of  approxi mately [ADDRESS_144691] been optimized to  achieve u niform sequence covera ge 
across all targets. The resulting selected libraries will be sequenced on an  Illumina HiSeq 2000 
and analy zed for somatic point mutations, s mall indels,  copy number a mplifications and 
deletions, a nd stru ctural rearrangements. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 22 -  
  
10.0  EVALUATION DUR ING TR EATMENT/I NTERVENTION  
 
 Pre-Rxa Day 1 
(of 21)g Day 8 
(of 21)g Day 15 
(of 21)g 
Dx H NSCC X    
Carbopla tin  X X  
Paclitaxel  X X  
 
 
Break  
Week Temsirolimus  X X 
H and Pb X X  
Complete b lood cell 
counts (CBC)c X X X 
Basic M etabolic Pan el 
(BMP), with magnesiu mc X X  
Liver Func tion Tests  
(LFTS), Lipid Pane lc,d X X   
PT, aPTT  X    
EKG  X    
Pregnancy Teste X    
Imaging Studiesf X    
Adverse Event  
Monito ring  Continuous  Monito ring for 
Adverse Events  
 
aSee Section  8 for requi red time frames for pre -treatment stu dies 
bDuring Cycle 1 of  the Phase I po rtion of the stu dy, patie nts will be evaluated for each  weekly 
treatment in cli nic by  p hysician and /or nurse.  A fter  Cyc le 1 in Phase 1, the requ irement 
will be one  MD clin ic visit per cycle, with add itional c linic visits sc heduled as needed.  In 
Phase II of  the study, t he requi rement will be one  MD clin ic visit per cycle, with add itional 
clinic visits scheduled  as needed.  
cTo faciliate the timely a dministration of chemotherapy on treatment days, CBC and  BMP with 
magnesi um level may be obtained 1  calend ar day  prior the ch emotherapy treatment date, if 
need be.  For Day  1 of  each cyc le, Liver Fun ction Tests and  Lipid Panel  may be obtained  
within 7 c alendar days prior to the  chemotherapy tre atment date, if  need be. 
Note in cl arification:  On Day 8, the  only req uired lab t est is CBC.  
dFor Cycle  [ADDRESS_144692] for women of childb earing  poten tial w ithin 14 days  prior to therapy. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 23 -  
  
fRadiologic  imaging (CT scan and/ or MRI of  neck, CT chest  [with our without  contrast], and 
appropr iate imaging of  other s ites of  measureable  diseas e) will be obt ained at bas eline 
and a fter every 2 cy cles to asse ss for response  to treatment (Please see Section 9.1.10 
regar ding o ption to perform subsequent i maging q3 cycles for patients who  remain on 
study a fter the imaging studies  at end  of cycle 6).  For pat ients who do not follow up at 
MSKCC after co mpletion of study t reatments, t he inve stigator and/or  the study t eam may 
attempt to  contact  [CONTACT_128242] t elephone for inter mittent follow up.g  Treatment may be 
given [ADDRESS_144693].  
 
 
 
11.0 TOXICIT IES/SIDE EFFECTS 
 
11.1 Toxicity  management:  general co nsidera tions 
 
Potent ial toxicities of  Temsirolimus, Paclitaxel,  and Carbopl atin are discussed in Se ction 5 of 
this pr otocol.  The following sec tions provide g uidelines for mandatory dose delays  and/or dose 
reduc tions for treatment-related toxicities. 
 
For pat ients who experi ence more than one tox icity, it is p ossible that su bsections 11 .2-11.12 
may provide con flicting recommendations for dose redu ctions.  If  a pat ient expe riences more 
than one to xicity req uiring dose del ay and/or do se redu ction and the re are con flicting 
recommendations for each, the in vestigator wi ll select the reduction  to the  lower dose  and/or  the 
longer  treatment delay.  
 
Even when the pat ient meets criteria for continu ed tre atment at full dose  per the protocol, the 
inves tigator retains the discretion to delay  t he next treatment and/or reduce dose  if  there are 
safety conc erns and/ or logistical issues.  Any dose redu ctions not spe cified in the protocol should 
be discus sed with the principal  investigator. 
 
Any patient  who requir es dose redu ction in  temsirolimus bel ow 15  mg weekly wi ll be removed 
from study.  Any patient  who requir es reduc tion in pacl itaxel below 60 mg/m2 weekly will be 
removed from study.  Any patie nt who requi red reduc tion in  carbop latin below AUC  [ADDRESS_144694] not be r e-escalated.  
 
Treat ment delays of  up to 21 tot al days per cy cle in temsirolimus (and/or  carbop latin and/or 
paclitaxel) are allowed.  
 
In the pha se I por tion of  the study, d ose redu ctions are not  allowed during  cycle 1.  P atients who 
requi re dose  reduc tion during cy cle [ADDRESS_144695] one cycle of treatment. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/[ADDRESS_144696] atin and pacl itaxel. As such, t he initial dose 
reduc tions are for the study drug, te msirolimus. 
 
The following dose red uction table will be u sed for myelosuppressio n: 
 
 
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel,  
Days 1 and 8  Carbopla tin 
Days 1 and 8  
Minus 1  15 mg 60 mg/m2 AUC 1.0  
1 15 mg 80 mg/m2 AUC 1.5  
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.5  
 
 
Dose reduc tions begin from the pati ent’s c urrent dose lev el. For exa mple, if  a patie nt is 
being treated at Dose L evel 2 and requires do se reduction, his next treatment would be at 
Dose Level  1. 
 
Day 1 of  Cycle 
 
ANC (K/m cL) and  
Plate let Count (K/mcL)  
ANC ≥ 1.5 and Plts ≥ 1 00:  Tre at 
without do se redu ction 
ANC < 1.5  and/or P latelets <10 0: 
Hold.  If  repeat ANC the next week  
≥ 1.5 and r epeat P lts next week ≥  
100, resu me treatment.  Dose 
reduc tion by  [CONTACT_128243] l evel is n ot 
mandatory, but is allowed at the 
discretion of  the inv estigator. 
Febrile Ne utropenia* : Hold unt il 
resolution. When A NC ≥ 1.5 and 
afebrile  and Plts ≥ 100,  may proceed 
but redu ce by 1 dose le vel 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
- 25 -  
 
 
Day 8 of  Cycle (ie, treatment week 2  of Cycle)  
 
ANC (K/m cL) and  
Plate let Count (K /mcL)  
ANC ≥ 1.0 and Plts ≥ 7 5: Treat  
without do se redu ction 
ANC < 1.0  and/or P latelets <75:  
Hold.  If  repeat ANC the next week  
≥ 1.0 and r epeat P lts next week ≥  
75, resu me treat ment wi thout dose 
reduc tion 
Febrile Ne utropenia* : Hold unt il 
resolution. When A NC ≥ 1.5 and 
afebrile  and Plts ≥ 100,  may proceed 
but redu ce by 1 dose le vel 
 
For pat ients who require  dose redu ctions on Day 8  (ie,  treatment week 2  of the Cycle), the do se 
reduc tion w ill also apply  to carbo platin on Day 1 of  the next cycle. 
 
 
 
 
*Febrile neutropeni a: The de finition of  febrile  neutrope nia is ANC < 1.0 and fever ≥ 38.5oC 
(CTCAE v.  3.0).  Any patie nt with febrile neu tropenia wi ll undergo app ropriate pr e-antibiotic 
evalu ation and will be admitted to hospi[INVESTIGATOR_128221] a ntibiotic therapy.  At the di scretion of  
the inv estigator, in patient hospit alization for empi[INVESTIGATOR_29121] a ntibiotics may be instit uted for any patie nt 
with ANC ≤  1.5 and fever ≥  38.0oC. 
 
Use of  stimulators of  erythropoie sis is allowed, a ccording  to established guidelines. 
 
11.[ADDRESS_144697] incidence of hepatic 
toxicity.   T emsirolimus, paclitaxel, and carbop latin can be associated with  abnor malities in liver 
function te sts (LFTs).  Because of  concern for the  poten tial of  the study drug (te msirolimus) to 
worsen LFT abnor malities asso ciated with the standard dru gs (carbo platin and pac litaxel), the 
initial d ose reductio ns are for the st udy drug te msirolimus. 
The following dose red uction table will be u sed for hepatic  toxicity: 
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel, 
Days 1 and 8  Carbopla tin 
Days 1and 8  
Minus 1  15 mg 60 mg/m2 AUC 1  
1 15 mg 80 mg/m2 AUC 1.5  
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.5  
 
Amended: 04/22/15  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 26 -  
  
 
 
Dose reduc tions begin from the pati ent’s c urrent dose lev el. For exa mple, if  a patie nt is 
being treated at Dose L evel [ADDRESS_144698] and ALT sh ould be dra wn.  The more abnor mal of the two va lues (AST or ALT)  
should be u sed in de termining t he dose. 
 
 AST or ALT: 
ALK PHOS: ≤ ULN >1X but ≤1.5X ULN >1.5X but ≤5X ULN >5X ULN 
≤ 1.[ADDRESS_144699] Full Dose Full Dose Treat at Full Dose, Or 
Treat at Re duced Dose, 
Or Hold, at discretion 
of investigator* Hold* , 2 
>1.5 X but ≤ 
2.5X ULN Full Dose Full Dose Hold or Treat at 
Reduced Dose, at 
discretion of 
investigator* Hold* ,2 
>2.5X but ≤ 
5X Full Dose Hold* Hold*, 1 Hold*,2 
>5X ULN Hold* Hold* Hold*, 2 Hold*, 2 
 
*If treatment is h eld, treatment should not resume unt il liver function te sts have “ recovered”, 
maximum 21 days.  “Recovered”  is defined as meeting  requirements for treat ment ac cording 
to this  table. 
 
1 Upon recovery, resu me treatment at full dose  or redu ced by 1 dose le vel, at  the d iscretion 
of the inves tigator. 
 
2Upon  recovery, resu me treatment at  next lower dose lev el 
 
11.3.2  Biliru bin 
 
Total b ilirubin > ULN but  ≤ 1.[ADDRESS_144700]:  May hold t reatment, t reat at full dose, or treat at 
reduced do se, at t he discretion of  the inves tigator 
 
Total b ilirubin > 1.[ADDRESS_144701]:  Hold t reatment  until s erum total bi lirubin is ≤ 1.[ADDRESS_144702] 
(maximum 21 days), t hen re -treat at next lower  dose lev el 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 27 -  
  
11.4 Mucosi tis/Stoma titis 
 
Mucosi tis/Stomatitis will  be asses sed accor ding to  clinical exam criteria. For management of 
musositis, supporti ve measures  such as anal gesics and oral  rinses will be administer ed accor ding 
to stan dard practice. 
 
Syste mic ad ministration  of imida zole antifungal  agents (ketocon azole, flucon azole, 
itracona zole, etc .) should be avoid ed in all patients due to  their potential to alter the 
metabolism  of temsirolimus and pacli taxel.  Th erefore, to pi[INVESTIGATOR_128222]. 
 
Temsirolimus and pac litaxel may be associ ated with mucosit is.  Because  of concern for the 
poten tial of  temsirolimus to cause mucosi tis an d/or intensify mucositis  associated wi th 
paclitaxel, the following  table calls for initial dose redu ctions in temsirolimus. 
 
The following dose red uction table will be u sed for mucosit is: 
 
 
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel,  
Days 1 and 8  Carbopla tin 
Days 1 and 8  
1 15 mg 80 mg/m2 AUC 1.5  
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.5  
Dose reduc tions begin from the pati ent’s c urrent dose lev el. For exa mple, if  a patie nt is being  
treated at Dose Level 2  and requ ires dose redu ction, his next  treatment would be at Dose Level 1. 
If a patie nt at Dose Level  1 exper iences mucositis  that requires dose redu ction, t he patient wi ll be 
removed from study.  
Guidelin es for dose red uctions/dose  delays are as follows:  
 
Grade 1 or  Grade 2 M ucositis: May hold, t reat at full dose,  or treat at next lower do se 
level,  at the discretion of  the inv estigator.  Dose reduction  is at the discretion of  the 
inves tigator. 
 
Grade 3 M ucositis:  Ho ld until  ≤ Grade 2, then  resume trea tment at next lower dose  level 
Grade 4 M ucositis:  O ff Study  
 
11.5 Nausea/Vomi ting 
 
All pa tients will receive anti-emetics and hydra tion, per in stitution al guidelines. 
 
The dose r eduction plan reflects concern for the  poten tial of  temsirolimus to worsen 
nausea/vo miting ass ociated with c arboplatin +  p aclitaxel.  As  such, the  initial dose reductions 
are for the  study drug, t emsirolimus. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 28 -  
  
The following dose red uction table will be u sed for nausea/ vomiting: 
 
 
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel, 
Days 1 and 8  Carbopla tin 
Days 1 and 8  
Minus 1  15 mg 60 mg/m2 AUC 1 
1 15 mg 80 mg/m2 AUC 1.5  
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.5  
 
 
Dose reduc tions begin from the pati ent’s c urrent dose lev el. For exa mple, if  a patie nt is being 
treated at Dose Level 2  and requ ires dose redu ction, his next  treatment would be at Dose Level  
1.For any p atient expe riencing naus ea and/or v omiting, the chemotherapy tre atment will be 
delayed u ntil any vo miting has res olved to ≤ Gr ade 1 (1 epi [INVESTIGATOR_85712] 24 h ours) and any  nausea has 
resolved  to ≤ Grade 1 (loss of  appet ite witho ut alteration in eating ha bits). 
 
For any pa tient exp eriencing ≥ Gra de 3  nausea and/or vo miting, tre atment will be given at t he 
next lower dose lev el when nausea a nd vomiting are ≤ Grade 1. 
 
11.6 Diarrhea  
Because of  concern for the poten tial for temsirolimus-associ ated di arrhea, the initial dose 
reduc tions are for the study drug, te msirolimus. 
 
The following dose red uction table will be u sed for diarr hea: 
 
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel,  
Days 1 and 8  Carbopla tin 
Days 1 and 8  
Minus 1  15 mg 60 mg/m2 AUC 1.5  
1 15 mg 80 mg/m2 AUC 1.5  
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.5  
Dose reduc tions begin from the pati ent’s c urrent dose lev el. For exa mple, if  a patie nt is being  
treated at Dose Level 2  and requ ires dose redu ction, his next  treatment would be at Dose Level 1.  
 
Grade 1 or  Grade 2 Di arrhea: 
Chemother apy tre atment may be continued at full dose, con tinued at t he next 
lower dose level, or held.  Antidi arrheals may be used as nee ded.  Dose r eduction 
is at the d iscretion of  the inves tigator. 
 
Grade 3 Di arrhea: 
In the e vent of diarrhea  requiring ho spi[INVESTIGATOR_059] (ie, Grade 3), supporti ve 
measures  may inclu de hydration, oc treotide, and  antidiarrheals. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 29 -  
  
Chemother apy tre atment will be h eld until diarrhea has i mproved to ≤ Grade 1, 
with dose r eductions  as follows:  
 
If Grade 3 diarr hea du ration is ≤ 48 hours, the n ext treatment may be 
given at full dose or at  the next low er dose lev el, at the discretion of  the 
inves tigator. 
 
If Grade 3 diarr hea du ration is > 48 hours, the n ext cyc le will  be given at 
the next  lower dose level 
 
Grade 4 di arrhea:  O ff Study  
 
11.7 Sensory Neuropathy  
 
Paclitaxel and carbop latin can be associated with  sensory ne uropathy.  T emsirolimus is unlik ely 
to cause sensory neuro pathy but we  cannot ex clude the pos sibility th at temsirolimus could 
worsen to n europathy a ssociated with  carbop latin and pac litaxel.  There fore, sensory neuropathy 
management features do se redu ctions for all t hree agents.  
 
If the pa tient develops G rade 1 or Gr ade 2 sensory  neuropathy,  chemotherapy tre atment may be 
given at full dose or may be held for ≤ 21 days, at  the di scretion of  the in vestigator. 
 
If a patie nt develops ≥ Grade 3 sens ory neurop athy, tre atment will be h eld. Upon reso lution to 
grade 1, treatment may resu me at the dose and s chedule sho wn in the following table  (regardless 
of the curre nt dose level): 
 
 
 
Temsirolimus, 
Days 1 and 8  Paclitaxel,  
Days 1 and 8  Carbopla tin 
Days 1 and 8  
15 mg 60 mg/m2 AUC 1  
 
An patient  who requir es reduc tion below this dose and sch edule wi ll be removed from the study.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 30 -  
  
11.8 Renal  Toxicity Mana gement  
 
If serum  creati nine is  ≥ 1.5 on plan ned tr eatment date, e stimate the  creatinine c learance (CrCl)  
by [CONTACT_128244] G ault Equa tion. 
 
Calcul ated Creati nine 
Clearan ce (CrCl)  Manage ment 
≥ 45 ml/min Hydrate as c linically indicated.   May treat at  full dose, 
treat at next lower dose level, or hold treatment, at the 
discretion of the investigator. 
<  45 ml/min Hold treatment for the week and hydrate as clinically 
indicated. 
 
If repeat CrCl  ≥ 45 ml/min, may res ume treatment at the 
next lower dose level. 
 
Carbopla tin and te msirolimus may be  associ ated with ren al toxicity.  Pac litaxel is unlikely to 
cause renal toxicity. There fore, d ose redu ction for renal  toxicity invol ves carbop latin and 
paclitaxel. 
 
For pat ients who require  dose redu ction for renal  toxicity, up on resol ution of renal to xicity (ie, 
creatinine clearan ce ≥ 45 ml/min) tr eatment will  be at t he reduced doses shown in the  following 
table: 
Temsirolimus, 
Days 1 and 8 Paclitaxel,  
Days 1 and 8  Carbopla tin 
Days 1 and 8  
15 mg 80 mg/m2 AUC 1  
  
 
If a patie nt requi res do se redu ction during t he middle of  a cycle (ie, the Day 8 or Day 15 dose), 
the dose reduction w ill continue for subsequent cycles as w ell. 
 
Any patient  who requir es reduc tion below the temsirolimus dose (15 mg) or the  carboplatin dose  
(AUC 1) will be re moved from study.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 31 -  
  
11.9 Dermatolo gic Toxic ity 
 
Temsirolimus and has been asso ciated with ras h.  Pacl itaxel is less likely to be asso ciated with 
rash.  As su ch, the to xicity manage ment plan calls for dose re ductions  in temsirolimus. 
 
The following dose red uction table will be u sed for rash:  
 
 
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel,  
Days 1 and 8  Carbopla tin 
Days 1 and 8  
1 15 mg 80 mg/m2 AUC 1.5  
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.5  
 
 
Dose reduc tions begin from the pati ent’s c urrent dose lev el. For exa mple, if  a patie nt is being 
treated at Dose Level 2  and requ ires dose redu ction, his next  treatment would be at Dose Level 1.  
If a patie nt at Dose Level  1 exper iences rash  that requires d ose reduc tion, the pat ient will be 
removed from study.  
 
Grade 1 :  No speci fic supporti ve care is usu ally needed or  indicated. 
 
Grade 2 :  May treat with  supporti ve measures, at  the di scretion of  the in vestigator. 
Options in clude: or al minocycli ne, topi[INVESTIGATOR_128223],  topi[INVESTIGATOR_47288], to pi[INVESTIGATOR_128224], diphenhyd ramine, and oral p rednisone (sho rt course).  Interruption of 
chemotherapy will be at the di scretion of  the in vestigator.  Dose redu ctions are not 
necess ary. 
 
Grade 3:   Hold che motherapy treatment un til resolution  ≤ Grade 2.  The  need for oral  or 
topi[INVESTIGATOR_128225] t he discretion of  the investi gator and may be  accompanied by 
a cult ure of  the affected area and a dermatology consult.   When toxi city resolves  to 
Grade 2 or better, the patient may re sume treat ment at  the ne xt lower dose  level.  
 
Grade 4 :  Off Study  
 
11.10   Hyper lipi[INVESTIGATOR_128226] 10.  
 
Temsirolimus and has been asso ciated with hy perlipi[INVESTIGATOR_035].  As such, t he dose red uction sc heme 
calls for dose redu ctions in temsirolimus. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 32 -  
  
The following dose red uction table will be u sed for hyperli pi[INVESTIGATOR_035]: 
 
 
 
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel, 
Days 1 and 8  Carbopla tin 
Days 1 and 8  
1 15 mg 80 mg/m2 AUC 1.5  
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.[ADDRESS_144703] do se lev el of temsirolimus (15 mg wee kly) who 
meets crit eria for further  temsirolimus dose redu ction wi ll be removed from study.  
 
Grade 1 hypercho lesterolemia (> upper limit of nor mal to 300  mg/dL or 7.75  mmol/L) or  
grade 1 hy pertriglyceridemia (> upper limit of normal to 2.5X upper li mit of normal): 
Continue c hemotherapy tre atment without any d ose redu ctions.  A statin or approp riate 
lipid-lowering agent may be sta rted at the discretion of  the investigator. 
 
Grade 2 hypercho lesterolemia (> 300 - 400mg/dL, or >7.75 - 10.34  mmol/L) or g rade 2 
hypert riglyceride mia (>  2.5 -5.0 X upper limit of nor mal):  Continue c hemotherapy 
treatment without any d ose redu ctions.  A statin or approp riate lipid-lowering medica tion 
should be u sed in add ition to di et, per  inves tigator’rs d iscretion. 
 
≥Grade 3 h ypercho lesterolemia (> 400  mg/dL or > 10.34 mmol/L)  or ≥  grade 3  
hypert riglyceride mia (>  5X upper l imit of normal):  Hold c hemotherapy tre atment.  A 
statin or ap propriate lipid-lowering  medication should be us ed in add ition to diet, per 
inves tigator’rs dis cretion.  When toxicity  resolves to Grade 2  or be tter, may resu me 
treatment at  full dose or  at the next lower  dose level, at the discretion of  the inve stigator. 
 
11.11   Inters titial Lung Disease (ILD)  
 
Both asy mptomatic ra diological cha nges (gra de 1) and sy mptomatic non -infectious p neumonitis 
(grade 2 =  not interfering with ac tivities of  daily living or grade 3 = in terfering w ith activities of 
daily living  and oxygen indic ated) have been no ted in pa tients rec eiving temsirolimus therapy. 
Any patient  who develops any new or worseni ng pul monary sy mptoms (ie, dyspnea  and/or 
cough) sho uld undergo either che st X-ray an d/or CT scan of  the chest.  
 
The dose r eduction scheme calls for dose redu ctions in te msirolimus. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 33 -  
  
The following dose red uction table will be u sed for ILD:  
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel, 
Days 1 and 8  Carbopla tin 
Days 1 and 8  
1 15 mg 80 mg/m2 AUC 1.5  
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.[ADDRESS_144704] do se lev el of temsirolimus (15 mg wee kly) who 
meets crit eria for further  temsirolimus dose redu ction wi ll be removed from study.  
 
Manage ment on In terstitial Lung Di sease (ILD)  
 
Worst Grade 
Pneumonitis  
Required Investigations Management of 
Pneumonitis  
Chemotherapy Treatment 
Grade [ADDRESS_144705] X -ray and/or CT 
scans of chest.  Consider 
pulmonary function testing 
including: spi[INVESTIGATOR_038], 
DLCO, and room air O2 
saturation at rest. Repeat 
chest x-ray/CT scan e very 
[ADDRESS_144706].  Consider 
pulmonary function testing 
including: spi[INVESTIGATOR_038], 
DLCO, and room air O2 
saturation at rest. Repeat 
imaging each month until 
return to baseline. Consider 
bronchoscopy Symptomatic only. 
Prescribe 
corticosteroids if cough 
is troublesome. May continue at Full Dose, 
Continue at next lower dose 
level, or hold treatment for up to 
[ADDRESS_144707] and 
pulmonary function testing 
including: spi[INVESTIGATOR_038], 
DLCO, and room air O2 
saturation at rest.  Repeat 
imaging each month until 
return to baseline. Consider 
bronchoscopy. Prescribe 
corticosteroids if 
infective origin is ruled 
out. Taper as medically 
indicated. Hold treatment until recovery to 
≤ Grade 1. May res tart protocol 
treatment within 3 weeks at a 
reduced dose (by [CONTACT_12691]) if 
evidence of clinical benefit. 
Patients will be withdrawn from 
the study if they fail to recover 
to Grade 1within [ADDRESS_144708] and 
required pulmonary 
function testing includes: 
spi[INVESTIGATOR_038], DLCO, and 
room air O2 saturation at 
rest. Repeat imaging each 
month until return to 
baseline. Bronchoscopy is 
recommended. Prescribe 
corticosteroids if 
infective origin is ruled 
out. Taper as medically 
indicated. Discontinue treatment. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 34 -  
  
11.12  Toxici ties Not Otherwise Speci fied 
 
For toxi cities not spe cifically addre ssed in Se ction 11, this s ubsection pr ovides gen eral 
guide lines. Because a potential role for the study  drug te msirolimus may be suspec ted in 
unanti cipated toxi cities, the dose reduction scheme will in itially call for dose redu ctions in the 
study drug,  as follows:  
 
Dose  
Level  Temsirolimus, 
Days 1 and 8  Paclitaxel,  
Days 1 and 8  Carbopla tin 
Days 1 and 8  
Minus 1  15 mg 60 mg/m2 AUC 1  
1 15 mg 80 mg/m2 AUC 1.5  
2 20 mg 80 mg/m2 AUC 1.5  
3 25 mg 80 mg/m2 AUC 1.5  
 
 
 
Any patient  who requir es reduc tion below “Dose Level Minus 1” will be removed from the 
study.  
 
The gener al approach  to toxicity manage ment will be: 
Grade 1:  T reat at full dose. 
Grade 2:  May hold, treat at full dose, or tr eat at next lower d ose lev el, at the disc retion of 
the inv estigator.  Dose r eduction  is at the di scretion of  the in vestigator. 
 
Grade 3:  Hold unt il ≤ Grade 2, th en resu me treatment at n ext lower do se lev el 
 
Grade 4:  Hold t reatment.  When to xicity res olves to ≤ Grade  2, may resu me treat ment at 
the next  lower dose level. 
 
The inves tigator retains the autho rity to remove any patie nt from study for any toxicity if he/she 
believes th at it is in the best interest of the patie nt to disco ntinue study treatment. 
 
12.0 CRIT ERIA FOR THERAP EUTIC RE SPONSE/OUT COME AS SESSME NT 
 
Radiologic  response c riteria are b ased on previo usly publ ished RECIST guidelines [56].  At 
baseline, t umor lesions  will be categorized  as follows:  Mea surabl e: lesions that  can be 
accur ately measured in at l east one  dimension ( longest d iameter to be recorded as  > [ADDRESS_144709] s can); Non measurab le: all other  lesions, inclu ding small lesions  (<[ADDRESS_144710] scan).  All measure ments wi ll be recor ded in metric nota tion by [CONTACT_2363]  a ruler or calipers.  All 
baseline ev aluations wi ll be per formed as clos ely as possi ble to the begin ning of  treatment and 
never more than 4 weeks be fore the beginning of  treatment. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 35 -  
  
Lesions co nsidered  to be  truly non measurab le include the following: bone lesions, 
leptomeningeal d isease,  ascites, p leural/pericardial effusion, inflammatory breast disease, 
lymphangitis cuti s/pulmonis, abdo minal masses that a re not confirmed and followed by i maging 
techniq ues, and cys tic lesions.  Tu mor lesions t hat are situated in a pre viously i rradiated area  are 
measurable only if  unequivocal growth can be documented in the bas eline scan co mpared to  a 
scan obt ained within one month of  radia tion treatment. 
 
MRI or Spi [INVESTIGATOR_128227], using a contiguous reconstru ction algorithm, will be u sed to 
chara cterize each ide ntified and rep orted lesion at baseline and  during follow-up.  Intr avenous 
contra st agents will be given, unl ess contr aindicated for medical reasons such as a llergy or other 
reasons, at the disc retion of the tre ating physi cian.  This is  to accent uate vascul ar structures from 
adjace nt lymph node  masses and  to help enhan ce liver and other visceral metasta ses. In pa tients 
in wh om the abdo men and pelvis  are being i maged, oral co ntrast age nts should be giv en to 
accent uate the bowel a gainst other soft-tissue masses.  Dur ing physic al exam  assess ment, 
clinically detected lesions will on ly be consid ered measurable  when they are super ficial (e.g., 
skin nodules  and palpa ble lymph no des).  Lesio ns on chest x -ray are acceptable as measurable 
lesions wh en they a re clearly defined and surro unded by [CONTACT_79927]. H owever, CT is 
preferable.  The sa me imaging  modality will be used throu ghout the study to measure dis ease, 
without i nterjection of  data from ultrasound or MRI exa minations, unle ss contr aindicated for 
medical rea sons such as  allergy or other reasons,  at the discretion of  the treating ph ysician 
 
Baseline E valuation:  Only pa tients with measurable d isease  at bas eline will be  included in t his 
protoc ol.  Only known sites of  disease, or a reas clinically suspected of  disease inv olvement, need 
be imaged.  All measurable l esions up to a maximum of five lesions per organ  and 10 lesions  in 
total, representative of  all inv olved organs, wi ll be iden tified as tar get lesions and rec orded and 
measured at base line. T arget lesions will be selected on the basis of  their size (those  with the 
longest diameter) and their s uitability for accu rate repeated  measur ements (either by [CONTACT_128245]). A sum of the longe st diameter for all  target lesions will be  calculated 
and repo rted as the ba seline sum  longest d iameter. The bas eline sum  longest d iameter will be 
used as the reference by  [CONTACT_128246].  All oth er lesions  (or 
sites of  disease) wi ll be identified as  nontarg et lesions and w ill also be recorded at baseline. 
Measure ments of  these  lesions are not req uired, but the presence or  absence of  each should be 
noted t hroughout follow -up. 
 
Evalua tion of target  lesions:  Co mplete Response (CR):  the di sappeara nce of all target lesion s; 
Partial Res ponse (PR):  at least a 3 0% dec rease in the sum  of the long est diameter of  target 
lesions,  taking as re ference the b aseline sum  longest d iameter; Prog ressive Disease  (PD):  at  least 
a 20% in crease in  the sum of the longest d iameter of  target lesions, ta king as reference the 
smallest s um longest d iameter reco rded since  the treatment sta rted, or  the appeara nce of one or 
more new l esions; S table Disease ( SD):  ne ither sufficient s hrinkage  to qualify for partial 
response n or sufficient i ncrease to q ualify for pr ogressi ve disease, taking  as reference the 
smallest s um longest d iameter since  the treatment started. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 36 -  
  
Evalua tion of nontarget  lesions:  C omplete Res ponse (CR):  the di sappearance of  all nontarg et 
lesion s; Sta ble Disea se (SD):  the p ersistence of  one or more nontarg et lesion(s); Pr ogressi ve 
Disease (P D):  the appe arance of  one or more new lesions a nd/or uneq uivocal pro gression of 
existing no ntarget lesions. Data from observat ion of  all target and non -target lesions will be 
combined in order to determine overall  response,  accor ding to the follow ing tabl e: 
Target  Non-Target  New  Lesions  Overall Re sponse  
CR CR No CR 
CR SD No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or no  PD 
Any PD Yes or no  PD 
Any Any Yes PD 
 
The best ov erall respon se is the best response r ecorded from the sta rt of treatment unt il disease 
progres sion/recurrence  (taking as reference for progressi ve disease t he smallest measure ments 
recor ded since the  treatment starte d).  In so me circu mstanc es, it may be di fficult to disting uish 
residu al disease from normal tissue.  When the evalua tion of  complete r esponse depends on this 
deter mination, it is  recomm ended that the  residual lesion be  investi gated by [CONTACT_123494]-needle 
aspi[INVESTIGATOR_1516]/biopsy or PET scan be fore confirming the co mplete response status. 
 
The minimal time inter val req uired between two  measur ements for det ermination of  overa ll 
response  is 4 weeks.  The dura tion of  overa ll response is measured from the time that 
measur ement criteria are met for complete respo nse or pa rtial response  (whichev er status is 
recor ded first) until the first date that recurrent or progres sive disease  is objectively d ocumented 
(taking as reference for progres sive disease  the smallest measurements r ecorded si nce the 
treatment starte d). The  duration of  overa ll complete respo nse is measured from the ti me 
measur ement criteria are first met for co mplete re sponse unt il the first d ate that recurrent disease 
is obj ectively docu mented.   Stable  disease  is measured from the sta rt of the tre atment unt il the 
criteria for disease progression is met (taking as  reference t he smallest measure ments recorded 
since  the treatment star ted). 
 
Radiologic  scans wi ll be reviewed by  a design ated member of the MSKCC Depart ment of 
Radiology.  When no nmeasura ble disease is being assessed,  the radi ologist and attending 
physic ian w ill con fer to deter mine the prese nce or absen ce of unequivoc al disease progression.  
  
 
13.0 CRIT ERIA FOR RE MOVAL F ROM STU DY 
 
If at any time the p atient develops p rogressi ve disease h e/she will be  taken off study and 
referred for alternative therapy.  
 
Patie nts may be re moved from the s tudy for pro tocol non -compliance.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 37 -  
  
If at any time the p atient develops u naccep table toxicity he/ she will be  removed from study. 
Participants can be re moved from the study at  any time if the study doct or feels th at it is in 
their best  interest  to do so. 
 
14.0 BIOSTAT ISTICS  
 
This is a single arm  Phase I/ Pha se II trial open to patie nts with rec urrent/metastatic HNSCC  
who did not rec eive more than 2 p rior cytotoxic therap ies for recurrent/metastatic disease. 
  
 
14.1 Part 1 (Phase 1)  
 
The pri mary objec tive of  this p art is to deter mine the phase  II-recommended dose of 
temsirolimus, when giv en in co mbination  to pac litaxel and c arbopl atin. This will be the 
recommended dose th at will be u sed in the P art II (Phase II) of the tr ial. 
 
Patie nts will be treated in cohorts of  size three-six and the d osage wi ll be escalated if the cli nical 
toxicity is accepta ble. A patie nt is considered  toxicity-free for the purpose  of the tr ial if he/she 
completes t he first c ycle of therapy (21 days) wi thout expe riencing dose  limiting toxi city (DLT, 
as desc ribed in se ction 4 .1.1). If  therapy is disco ntinued du ring the first cycle for reasons other 
than to xicity (see Se ction 13.0), an a dditional patient may be enrol led at  that dose  level to ensure 
adequate  evaluation of  toxicity. However, pa tients will not be rep laced unless t hey cannot be 
evalu ated for DLT in cycle [ADDRESS_144711] udy. Three d ose lev els wi ll be 
conside red for esc alation, as desc ribed in Sec tion 4.1.1. No within -patient escalation will be 
performed. 
 
The dose e scalation sc heme is as follows:  
1.   If  none of  the in itial three pat ients at a given dose  level experience DLT, the next dose 
level w ill be studied.  
2.   If  one of  the ini tial three patients at a given dose  level exp eriences DLT, three additional 
patients wi ll be treated at the same dose lev el. Escalation wi ll continue o nly if there has 
been no add itional DLT observed.  
3.   If  two or more pa tients experie nce DLT at a giv en dose, the previous do se will be 
declared the  maximum tolerated dose (MTD).  
4.   If  only thr ee patients we re treated at a dose under  conside ration as MTD, an addi tional 
three patients will be  treated at that level to  confirm previous resu lts. 
The MTD will be the p hase II  recommended do se.  However, if  the MTD is not e xceeded at dose 
level 3,  then dose lev el 3 will be  the phase II  recommended  dose.  
 
The design is constr ucted to minimize the cha nces of escal ating the dose  when the p robabi lity of 
DLT is high, and maximize the cha nce of  escal ating the do se when the p robabi lity of  DLT is 
low. The probabi lities of escala ting to the next dose lev el under this sch eme for vari ous true 
toxicity rates are gi ven in the ta ble below.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 38 -  
  
 
 
Toxicity r ate 0.10 0.20 0.30 0.40 0.50 
Probability  of escal ation 91% 71% 49% 31% 17% 
 
 
A minimum of 2 and a  maximum of 18 patie nts will be required to co mplete this p hase of the 
trial. With a planned a ccrual of  2 pat ients/month, this p art of the study sh ould be co mpleted 
within ≤ 9  months.  
 
 
14.2 Part 2 (Phase II)  
 
In Part 2,  the primary endpoint wi ll be obje ctive radiograp hic response  rate (CR+PR) a fter 2 
cycles  (6 weeks) of  therapy.  As a hi storical co ntrol, Gibson et al reported a response  rate of  26% 
with cis platin + pac litaxel as p alliative the rapy for pa tients who had not rec eived p rior 
chemotherapy for recur rent/metastatic HNS CC [6].  In the cu rrent study, we esti mate that h alf of 
patients wi ll receive stu dy treatment as first line therapy for recurrent/metastatic disease.  We 
estimate th at half of the study pa tients will receive study treatment as second or th ird line 
therapy, for which the h istorical estimate for objecti ve resp onse ra te with  palliative 
chemotherapy is 15% [57-58].  As such, the e stimated response ra te for this pa tient popula tion is 
p0= (.26 X 0.5) +  (0.15  X 0.5)  = 0.21.  
 
A Simon opti mal two -stage design w ill be e mployed to ass ess the primary endpoint of 
radiog raphic  response  rate (by [CONTACT_128247]) at 6 weeks a fter th erapy start (2  cycles).  A 21% 
respons e-rate is con sidered not pro mising, a 41%  response  rate is con sidered pro mising, and the 
probab ilities of a Type I error  (falsely accep ting a non -promising th erapy) and Type II error 
(falsely  rejecting a promising t herapy) are set to 0.[ADDRESS_144712]  a response out  of a total of  36 patie nts enrolled, the  regimen 
will be co nsidered wort hy of further investi gation. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 39 -  
  
We anticip ate that  the p atient popul ation in t he study will be  consis tent with the historical contr ol 
popula tion as regar ds prior treatment.  To ensure  consis tency between the  study popu lation and 
the hi storical con trol po pulation: 
● In the first part of  the two stage de sign, no  more than [ADDRESS_144713] 0 
prior c hemotherapy  regimens for recurren t/metasta tic disease,  and no more than 6 
of 11 patien ts will ha ve had 1 or 2 pr ior che motherapy re gimens for recu rrent 
metastatic disease.  No more than 6 patients in each group (no  previous  therapy  
vs. 1-2 pre vious cycle s) should be in cluded in first part of  the two stage de sign. 
Accrual  in each group will stop wh en the maximum number of  patients per group 
is reached.  
● For the e ntire accr ual to the phase  II portion of  the study, no  more than [ADDRESS_144714] 0 pri or chemotherapy regi mens for recur rent/metasta tic disease, 
and no more than [ADDRESS_144715] had 1 or 2 pri or chemotherapy 
regimens for recu rrent metastatic disease.  No more than 20  patients in each group 
(no previo us therapy vs.  1-2 previo us cycle s) should be in cluded in the  total ph ase 
II popul ation.  Accrual  in each gro up will st op when the maximum number of 
patients per group is reached.  
 
All the p atients enr olled in the  trial will be included in the main anal ysis of the objec tive 
response  rate, even if  there are major protoc ol deviations. Pa tients who do  not co mplete the first 
two cycles of treatment (due to any of the cr iteria listed in S ection 13.0 or to deat h) are 
conside red non-respon ses. 
 
The 6 patie nts from Part 1 who are t reated at the phase II  recommended  dose will be included  in 
the e fficacy  analy sis for response  rate.  As such, a minimum of  5 and a  maximum of 30 
additional patients need  to be enr olled in Part 2  to achieve  the sample si ze of 11 to 36 evalua ble 
patients. With an expec ted accru al rate of 1.5 pat ients/month, this pha se of the study s hould be 
completed in ≤ [ADDRESS_144716] one dose  of study treatment. 
 
Overall s urvival w ill be estimated u sing Kaplan -Meier methodology, wi th time orig in at the  start 
of the tre atment. 
 
Data anal ysis for corr elative stu dies will be d escriptive. The antibod ies whose expre ssion 
patterns wi ll be inve stigated by [CONTACT_128248] (TMA) int errogation are  listed in section 9.2. 
For each a ntibody, each  tumor sample will be  scored as “po sitive” or  “negative.” For 
immunohistoche mistry, positi vity w ill be de fined as at least 30% of  tumor cells stained for the 
probed an tigen  [51]. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 40 -  
  
We will ex plore if positive/neg ative status for each antibody  may be ass ociated with  objec tive 
radiog raphic  response  to study t reatment using n on-parametric Wilcoxon s tatistics.  On ly 
patients who  already ha ve biopsy or surgic al pathology material co llected as part of  routine care 
at time of diagnosis or  at any point  in the manage ment of  the patients HNSCC will contrib ute to 
this a nalysis. No resear ch biopsies  are planned  in the cour se of the study.  We anticip ate that 
archi ved tissue for corr elative studies will be a vailable for ap proximately 30 subje cts in the 
study.  
 
14.3 Accrual ra te 
 
The proje ction of  2 acc ruals per month is ba sed on prior accrual rates in the HN DM T, and also 
reflects the expansion of  the HN res earch pro gram.  Our service recently completed a phase II 
study of  gemcitabine +  pemetrexed for patie nts with advan ced HNS CC (MSK IRB 06-087). 
Accrual of  25 patie nts was co mpleted between 10/2006 and  2/2008 (1.5  accru als per month). 
Our HN service i ncluded [ADDRESS_144717] who will  
join our group in  8/[ADDRESS_144718] udy, the four MSKCC re gional n etwork affiliates  (Commack, NY; Phelps, NY; 
Rockville Center, NY;  Basking Ri dge, NJ) will  be par ticipating si tes to further  enhance ac crual 
in the ph ase II portion of  the study.  
 
15.0 RES EARCH PARTI CIPANT  REGISTRAT ION AND  RANDOM IZATION 
PROCE DURES  
 
15.1 Research Parti cipant  Registra tion 
 
Confirm eligibi lity as defined in the  section en titled Cr iteria for Pat ient/Subject  
Eligibility. 
 
Obtain in formed consent, by [CONTACT_128249].  
During the registration process  registering  individuals wi ll be requi red to  complete a 
protoc ol specific Eli gibility Check list. 
 
All pa rticipants must be regi stered through the P rotocol P articipant Reg istration (PPR) 
Office at M emorial Slo an-Kettering Cancer Cen ter. PPR is available M onday throu gh 
Friday from 8:30am  – 5:30pm at [ADDRESS_144719] be su bmitted v ia the 
PPR Electr onic Regi stration System  (http://ppr/). The co mpleted sign ature page of  the 
written con sent/RA or verbal script/RA, a c ompleted E ligibility Check list and other 
relevant do cuments must be uploaded  via the PPR  Electronic  Regist ration Syste m. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 41 -  
  
16.0 DATA  M ANAGEM ENT IS SUES  
 
A Research  Study Assis tant (RSA) will be assigned to the  study.  The re sponsibi lities of the RSA 
include project co mpliance, data  collection, ab straction and  entry, d ata reporting, re gulatory 
monitoring,  problem  resolution  and prioritization, and coor dinate the a ctivities of  the protoc ol 
study t eam. 
 
The data c ollected for this study wi ll be ent ered into a sec ure databa se.  Source doc umentation 
will be a vailable to  support the computerized p atient r ecord.  
 
16.1 Quality As surance  
 
Weekly reg istration reports wi ll be generated to  monitor pa tient ac cruals and co mpleteness of 
registration data.  Rout ine data qu ality repo rts will be ge nerated to ass ess missing data  and 
inconsi stencies.  Accr ual rates  and e xtent and  accuracy of  evaluations and  follow -up will be 
monitored periodically throughout the study  period and pot ential prob lems will be brought to  the 
attention of  the study team for discussion and a ction. 
 
 
 
16.2 Data and Safety Mon itoring  
 
The Data a nd Safety Monito ring (DSM) Plans at Memorial S loan-Kettering Cancer C enter 
were appro ved by [CONTACT_941] N ational Canc er Institute in Septe mber 2001.  The plans add ress the 
new polic ies set forth by  [CONTACT_128250] “Policy of  the National C ancer 
Institute for Data and S afety Monit oring of  Clinical Tr ials” which can be  found at: 
http://cancertrials.nci.nih.gov/res earchers/ds m/index.ht ml. The DSM Plans at MSKCC were 
established  and are monitored by [CONTACT_128251].  The MSKCC  Data and 
Safety Monitoring P lans can be found on the M SKCC Intranet a t: 
http://mskw eb5.mskcc.o rg/intra net/_asset s/_tables/co ntent/359709/DSMPlans07.pdf  
 
There a re several different mechanis ms by [CONTACT_128252],  safety 
and qual ity. There a re institutional processes  in place for qua lity assu rance (e.g., prot ocol 
monitoring,  compliance and data v erification au dits, therapeutic response,  and sta ff education 
on cli nical research QA) and depa rtmental procedures for quality con trol, plus t here are two 
institutional  committees that are responsible for monitoring  the ac tivities of our clin ical trials 
progra ms.  The co mmittees: Data and Safety  Monitoring Committee (DSM C) for Phase I and 
II clinical trials, and  the Data and Safety  Monitoring Board (DSM B) for Phase I II clinical 
trials, report to the Cen ter’s Rese arch Council and  Institutional Review Board.  
 
During the protoc ol dev elopment and review pr ocess, each protocol  is assessed for it’s level 
of risk and degree of  monitoring re quired.  Ev ery type of  protocol  (e.g.,  NIH sponsored, in - 
house spon sored, indu strial spons ored, NCI coopera tive gro up, etc.) w ill be addres sed and the 
monitoring  procedu res will be established  at the time of protocol a ctivation. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 42 -  
  
17.0 PROTE CTION OF HUMAN SUBJE CTS 
 
Inclu sion of  Children  in Research  
 
This prot ocol/project does not in clude children b ecause t he number of  children is  limited 
and because  the majority  are already  accessed by  a nationwide  pedia tric cancer research 
network.  This st atement is ba sed on  exclu sion 4b of the NIH Policy and  Guidelin es on 
the In clusion of Childr en as Par ticipants in Re search Inv olving H uman Subjec ts. 
 
17.1 Privacy  
 
MSKCC’s Privacy O ffice may allow the use and  disclos ure of protected health 
information pursuant  to a completed and signed  Research Author ization form.  The use 
and dis closure of  prote cted hea lth information will be  limited to the  individuals des cribed 
in the Res earch Author ization form.  A Research  Authoriz ation form must be co mpleted 
by [CONTACT_128253].  
 
 
 
17.2 Serious Adverse Event  (SAE) Re porting  
 
Any SAE  must be rep orted to the  IRB/PB as soon as possi ble but no l ater than 5 c alendar 
days. The IRB/PB requires a Clinical Rese arch Database  (CRDB) S AE report be 
submitted e lectro nically to the SAE Of fice at [EMAIL_203]  contai ning the following 
information:  
Fields pop ulated from the CRDB : 
• Subjec t’s name (genera te the report  with only initials if it will be se nt outside of  
MSKCC)  
• Medic al record nu mber 
• Disease/ histology (if  applicable) 
• Protocol n umber and t itle 
 
Data needi ng to be en tered: 
• The date t he adverse  event occu rred 
• The adverse  event  
• Relatio nship of the adve rse event  to the treatment (drug, dev ice, or i ntervention)  
• If the AE was expe cted 
• The seve rity of the AE  
• The int ervention 
• Detai led te xt that includes the following in formation: 
o A explana tion of  how t he AE was handled  
o A descrip tion of the sub ject's condi tion 
o Indic ation if the sub ject remains on the study  
o If an amendment will need to be made to the protocol an d/or consent form 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 43 -  
  
 
The PI’s si gnature  and the date  it was signed are requi red on the co mpleted report.  
 
17.2.[ADDRESS_144720] follow -up on Adverse Events as 
requi red by [CONTACT_2371]. 
 
The term  “Serious Adv erse Even t” (or “SAE”) shall mean any adverse drug exper ience 
occur ring at  any dose th at results in any of  the following out comes: death,  is Life-Threatening,  as 
defined below, requires inpatient hospi[INVESTIGATOR_1324], 
results in a persistent or significant disab ility or  incapa city, results  in a congenit al anomaly or 
birth defect, results in cancer, or results in an important medical event. Important medical events 
which are AEs that may not result in death , be Life-Threaten ing, or requir e hospi[INVESTIGATOR_128228],  based upon  appropr iate medical jud gment, they  may jeopardize t he 
Study Subj ect and may requir e medical or surgical interventi on to prevent one of the outcomes 
listed in this definition . Examples of such medical event s includ e allergic bronch ospasm 
requirin g intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in inp atient hosp italization, or the develo pment of  drug 
dependency  or drug abu se. 
 
In add ition to complying with a ll applicable regulatory reporting laws and  regul ations,  Institution 
will ens ure that the  Investigator report the follow ing in formation to Grant or and NCCN  in 
writing via fax within o ne business day of  the o ccurre nce, us ing the cov er page provi ded as 
Appendix B hereto,  and referencing  the appl icable Protoc ol number that  is assigned by [CONTACT_128254]. Such re port sh all be directed to  NCCN via fax at 215 -358-7699 or e - 
mailed to [EMAIL_2528]  and to P fizer U.S. Clinic al Trial Dep artment at 1 -866-997- 
8322:  
 
(a) All SAEs;  
 
(b) Reports  of pregnan cy exposure (pregnancy encompasses the en tire course of 
pregnancy and deliv ery, perin atal and neonat al outcomes, even if  there were no abn ormal 
findings; bo th maternal  and pater nal exposure is collected); 
 
(c) Reports  of lactation exposure;  
 
(d) Overdose (with or without an SAE);  
 
(e) Abuse (use for no n-clinical reasons with or  without an  SAE); 
(f)  Inadv ertent or a ccidental  exposure; and  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 44 -  
  
(g) Follow -up in formation reg arding any of  the above.  
 
The Inves tigator sho uld include h is or her a ssessment of  the causal  relationship bet ween each  
SAE and the Grantor pr oduct in  the form faxed to Grantor and  NCCN. 
 
17.3 Risks, Ben efits, Tox icities/side  effects 
 
Potent ial risks to hu man subje cts include drug related to xicity, pain and d iscomfort 
associ ated with mucosit is, temsirolimus side e ffects (S ection 5.1), pac litaxel side effects 
(Section 5. 2), carbo platin side e ffects (Sec tion 5 .3) , pla cement of IV cat heters, 
phleboto my, and possib le psycholo gical d iscomfort from the stre sses a ssociated with 
obtaining imaging stu dies (eg, CT  scan, PET scan).  All e fforts will be made to av oid any 
complicati on by [CONTACT_128255]’ symptoms, providing  appropriate 
management, and monitoring blood  tests. 
 
If an adver se medical event occ urs, the pat ient will first co ntact the primary oncologi st or 
the Pri ncipal Inves tigator. At nights  and on weekends, the re is an oncolo gy physic ian on 
call at all times.  Patients may eith er call or co me directly to the urge nt care ce nter at 
Memorial Hospit al (or to their local emergency ro om) to be s een.  Patie nts suffering 
serious  adverse reactions must be ca refully followed and all  follow -up information a lso 
recor ded. 
 
17.4 Alternati ves/options  
 
Participation in this  trial is volunt ary. Depending on the spe cific de tails of the situation, 
patient options without being in a  study might in clude: 
• Other pa lliative che motherapy o ff study.  For ex ample, carb oplatin and paclitaxel, 
without temsirolimus. 
• Participation in a di fferent clinical trial 
• Best suppor tive c are 
 
 
 
17.5 Financial Costs/Burde ns 
 
The patient will be  responsible for all costs related to treatment and co mplications of 
treatment.  Costs to t he patient (third party  insurer) wi ll include the co sts of carbop latin, 
paclitaxel, hospi[INVESTIGATOR_602], routi ne blood te sts and diagnos tic studies, o ffice vi sits, 
baseline EKG, and doctor’s fees.  Patients will not be ch arged for any r esearch  tests 
performed on rese arch specimens. 
 
Temsirolimus is pro vided by P fizer and there fore is not b illable to re search participants. 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/[ADDRESS_144721] sign an 
IRB/PB -approved cons ent form indicating  their consent  to participate. This conse nt form 
meets the r equire ments of  the Code of  Federal Regula tions and the In stitutional Rev iew 
Board/Pri vacy Board of  this Cen ter. The consent  form will i nclude t he following:  
 
1.   The nature  and objec tives, poten tial risks and be nefits of  the intended study. 
2.   The length of study and the lik ely follow-up requ ired. 
3.   Altern atives to the proposed study. (This will  include av ailable standard and 
inves tigational th erapi[INVESTIGATOR_014]. In add ition, patients wi ll be o ffered an option of 
supporti ve care for therapeutic  studies.) 
4.   The na me of the inv estigator(s) responsible for the protoc ol. 
5.   The right of  the pa rticipant to a ccept or refuse st udy int erventions/in teractions and 
to withd raw from partic ipation at any time. 
 
Before any protoc ol-specific pro cedures can be carried out,  the consen ting pro fessio nal 
will fully e xplain the as pects of  patient pri vacy concerning  research s pecific information. 
In add ition to signing  the IRB In formed Consent, a ll patients must agree to the Res earch 
Authoriz ation co mponent of the in formed consent form. 
Each par ticipant and co nsenting profession al will sign the  consent form. The par ticipant 
must rec eive a copy of  the signed  informed consent form. 
 
19.0 REF ERENCES  
 
1. Campone, M., et al., Safety and ph armacokine tics of pa clitaxel and t he oral mTOR 
inhib itor everolimus in advanced so lid tumors. Br J Cancer, 2008. 2009 Jan 6 [Epub 
ahead of print] . 
2. Fury, M.G., et al., Phase I study of everolimus (E; RAD00 1) + low dose weekly  cisplatin 
(C) for pati ents with ad vanced so lid tumors:  Pre liminary res ults. J Clin  Oncol 27, 2009 
(suppl; abs tr e14527) . 
3. 
http://www.cli nicaltrials.gov/ct 2/show/NCT004 [ZIP_CODE]?in tr=temsiroli mus+pac litaxel&rank=1.  
4. Colevas, A.D., Chemot herapy op tions for patients with meta static or rec urrent squa mous 
cell carcin oma of the h ead and neck.  J Clin Oncol, 2006. 24: p. [ADDRESS_144722] iere, A.A., et al., Randomized comparison  of cis platin plus flu orouracil versus 
methotrex ate in advanc ed squamous -cell carcin oma of the h ead and nec k:  A Southw est 
Oncology Group Study.  J Clin Onco l, 1992. 10: p. 1245 -1251.  
6. Gibson, M.K., et al., Randomized phase I II evaluation of  cisplatin plus fluorouracil 
versus cisplatin plus  paclitaxel  in advanced he ad and canc er (E139 5):  An Intergr oup 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 46 -  
  
Trial of  the Eastern Cooperat ive Oncology Gro up. J Clin Oncol, 2005. 23: p. 3562 -3567. 
7. Vermorken,  J.B., et al.,  Open -label,  uncontro lled, multice nter phase II study to ev aluate 
the e fficacy and toxi city of cet uximab as a single  agent in p atients w ith recurrent an d/or 
metasta tic squamous ce ll carcinoma of the head  and neck who fai led to respond to 
platinum -based chemot herapy. J Clin Oncol, 2007. 25: p. [ADDRESS_144723] atic/recu rrent head and neck cancer.  J Clin Oncol,  
2005. 23: p. 8646 -8654.  
9. Vermorken,  J.B., et al., Platinum -based chemoth erapy plus c etuximab in head and ne ck 
cancer. New Engl J Med,  2008. 359: p. 1116 -1127.  
10. Molinolo,  A.A., et al., Disse cting the Akt/Mammalian Targ et of Rapamycin Signa ling 
Network:  Emerging Re sults from the  Head and Neck Cancer  Tissue Arr ay Initiative. Clin 
Cancer Res,  2007. 13: p. [ADDRESS_144724] -targeted therapy  in 
patie nts with recurre nt and/or met astatic squamous ce ll carcinoma of the  head and neck. 
J Clin Onco l, 2006. 24: p. 2659 -2665.  
12. Aissat, N., et al., Antiproliferative effects of rap amycin as a single age nt and in 
combination  with carbo platin and p aclitaxel  in head and ne ck cancer cell lines. Cancer 
Chemother Phar macol, 2008. 62: p. 305 -313. 
13. Nathan, C. -A.O., et al., Mammalian target of rapamycin inh ibitors as p ossible a djuvant 
therapy  for microscopic  residual disease in head  and neck s quamous cell  cancer. Cancer 
Res, 2007. 67: p. 2160 -2168. 
14. Amornph imoltha m, P., et al.,  Mammalian tar get of rapamyc in, a molecu lar target  in 
squamous cell c arcino mas of the head and neck.  Cancer Res, 2005(65): p.  9953-9961.  
15. Shi, Y., et a l., Rapamycin enhances  apoptosis a nd increas es sensi tivity to cispl atin in 
vitro. Cancer Res, 1995. 55: p. 1982 -1988.  
16. Beuvink, I.,  et al., The mTOR inhibi tor RAD001  sensi tizes tumor cells  to DNA -dama ge 
induced ap optosis  though inhib ition of p21 tran slation. Cell, 2005. 120: p. [ADDRESS_144725] can cer cells. Clin Cancer Res,  
2004. 10: p. 7031 -7042.  
18. Faried, L.S.,  et al.,  Inhibition of  the mammalian target of rap amycin (mTOR) by 
[CONTACT_128256] c hemosensti vity of CaSki cells to pac litaxel. Eur J  Cancer, 20 06. 42: 
p. 934 -947. 
19. Wangpaichi tr, M., et al., Inhib ition of mTOR restores cis platin sensi tivity through down - 
regula tion of growth and  anti-apoptotic pr oteins. Eur J Phar m, 2008. 591: p. [ADDRESS_144726] iere, A., et al., Final report of a phase II evalua tion of  paclitaxel  in patie nts with 
advanced s quamous cell  carcinoma of the head and neck:  An  Eastern Cooperat ive 
Oncology Group Trial (PA39 0). Cancer, 1998.  82: p. 2270 -2274.  
21. Harding, M .W., Immun ophilins, m TOR, and ph armacodynamic stra tegies for a t argeted 
cancer t herapy. Clin Ca ncer Res, 20 03. 9: p. 2882-2886.  
22. Hidalgo, M.,  et al., A ph ase I and ph armacokine tic study of temsirolimus (CCI-779) 
administe red intra venously da ily for 5 days eve ry 2 weeks for  patie nts with advanced 
cancer. Clin Cancer Res,  2006. 12: p. 5755 -5763.  
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 47 -  
  
23. Atkins, M.B., et al., Randomized phase II study of multi ple doses of CCI -779, a novel 
mammalian target of rapamycin kin ase inhi bitor, in pat ients with advan ced refra ctory 
renal c ell carcinoma. J Clin Oncol,  2004. 22: p. 909 -918. 
24. Hudes, G., et al., Temsi rolimus, In terferon A lfa, or Both for Advanced R enal Cell  
Carcinoma. New Engl J Med, 2007. 356: p. [ADDRESS_144727] ever y-3-weeks administr ation of carbopla tin and pacl itaxel 
for pat ients with pre viously unt reated advanced  non-small -cell lung ca ncer. J Clin Oncol, 
2008. 26: p. 468 -473. 
26. Perez, E.A., et al., Two concurrent phase II  trials of pac litaxel/carbo platin/tra stuzumab 
(weekly or every-three-week sched ule) as firs t-line therapy  in women with HER -[ADDRESS_144728] can cer:  NCCTG s tudy 983252. Clin Brea st Cancer, 20 05. 6: 
p. 425 -432. 
27. Salama, J.K ., et al.,  Induction c hemotherapy and  concurrent  chemoradiot herapy for 
locore gionally advanced  head and neck cance r: a multi -institutional ph ase II trial 
investigating three ra diotherapy d ose levels. Ann Oncol, 2008. 19: p. [ADDRESS_144729] atin, a nd fluoroura cil ind uction  chemother apy fo llowed by [CONTACT_128257]. J Clin Oncol, 2005.  23: p. 8636 -8645.  
29. Posner, M.,  et al., Cisplatin and fluorouracil alone or with d ocetax el in h ead and  neck 
cancer. New Engl J Med,  2007. 357: p. 1705 -1715.  
30. Vermorken,  J.B., et al.,  Cispla tin, fluorouracil,  and doceta xel in un resectable head and 
neck canc er. New Engl J Med, 2007. 357: p. 1695 -1704.  
31. Oza, A.M., et al., Phase I study of temsirolimus (CCI - 779), carbopla tin, and pacl itaxel 
in pat ients with advan ced solid tum ors:  NCI CTG IND 179.  J Clin Oncol  27:15s, 20 09 
(suppl;  abstr 3558).  
32. Beuvink, I.,  et al., The mTOR inhibi tor RAD001  sensi tizes tumor cells  to DNA -dama ged 
induced ap optosis  through inhib ition of p21 tr anslation. Cell, 2005. 120(6): p. 747 -59. 
33. Wendel, H.G., et al., Survival sign alling by A kt and eIF4E in  oncogenesis  and cancer 
therapy. Nature, 2004. 428(6980): p.  332-7. 
34. Qiu, W., et al., PIK3CA mutations  in head and neck squamous ce ll carcinoma. Clin 
Cancer Res,  2006. 12(5): p. 1441 -6. 
35. Qiu, W., et al., A novel mutation of STK11/LKB1  gene leads  to the loss of cell growth 
inhib ition in head and neck squamous ce ll carcinoma. Oncogene, 2006. 25(20): p. 2937- 
42. 
36. Nathan, C.O., et al.,  Mammalian ta rget of rapa mycin in hibitors as possi ble adjuvant 
therapy  for microscopic  residual disease in head  and neck s quamous cell  cancer. Cancer 
Res, 2007. 67(5): p. 21 60-8. 
37. Brown, R.E ., et al.,  Morphoproteom ic and pharmacoproteom ic ration ale for mTOR 
effectors as therapeu tic targets in head and neck  squamous cell c arcino ma. Ann Clin Lab 
Sci, 2006. 36(3): p. [ADDRESS_144730].  Clin Cancer  Res, 2008. 14(19): p. 6 228- 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 48 -  
  
36. 
39. Zecchin, K .G., et al., High Bcl -2/Bax ratio  in Walker  tumor cel ls prot ects mitochon dria 
but does not  prevent H 2O2-induced  apoptosis via calci neurin pathways. J Bioenerg 
Biomembr, 2007. 39(2): p. 186 -94. 
40. Sun, S.Y., et al., Activation of Akt a nd eIF4E su rvival p athways by [CONTACT_128258] -mediated 
mammalian target of rapamycin inh ibition. Cancer Res, 200 5. 65(16): p.  7052-8. 
41. Wendel, H.G. and S .W. Lowe, Reversing drug resista nce in vivo. Cell Cycle, 2004.  3(7): 
p. 847 -9. 
42. Wendel, H.G., et al., Determinants of sens itivity and resi stance to rapa mycin- 
chemother apy drug combinations  in vivo. Canc er Res, 2006. 66(15): p. 7639-46. 
43. Nathan, C.O., et al., Detection of the proto -onco gene eIF4E in surgical margins may 
predi ct recurrence in head and neck  cancer. Oncogene, 1997. 15(5): p. 579-84. 
44. Wendel, H.G., et al., Dissecting eI F4E action in  tumorigen esis. Genes Dev, 2007. 21(24): 
p. 3232 -7. 
45. Silva, R.L. and H.G.  Wendel, MNK, EIF4E and targeting  translation  for therapy. Cell 
Cycle, 2007.  7(5). 
46. Mavrak is, K.J., et al., Tumorigenic activity and  therapeu tic inhibi tion of  Rheb GTPa se. 
Genes Dev, 2008. 22(16): p. 2178 -88. 
47. Mavrak is, K.J. and H.G. Wendel, Translation al control and cancer ther apy. Cell Cy cle, 
2008. 7(18): p. 2791 -4. 
48. Wendel, H.G., et al., Loss of p53 i mpedes the a ntileukemic response to BCR-ABL 
inhib ition. Proc Natl Ac ad Sci U S A,  2006. 103(19): p. 7444 -9. 
49. Mills, J.R., et al., mTORC1 promotes surviv al through trans lational  control of Mcl-1. 
Proc Natl Acad Sci U S A, 2008. 105(31): p. 1 0853-8. 
 
50. Herrington,  J.D., H.T. Tran, and M .W. Riggs,  Prospec tive BMI ev aluation of carbo platin 
AUC dosing in pat ients with a BMI  >= 27 or c achexia. Cancer Che mother Phar macol, 
2006. 57: p. 241 -247. 
51. Wendel, H. -G., et al., Dissecting eI F4E action in  tumorigen esis. Genes Dev, 2007. 21: p. 
3232-3237.  
52. Mavrak is, K.J., et al., Tumorigenic activity and  therapeu tic inhibi tion of  Rheb GTPa se. 
Genes Dev, 2008. 22: p. 2178 -2188.  
53. Puig, P., et al., p73 expr ession in hu man normal and tumor ti ssues:  l oss of p73alpha 
expres sion is associ ated with tumor progression  in bladder c ancer. Clin Cancer Res,  
2003. 9: p. 5642 -5651.  
54. Maeda, T., et al., Role of the prot o-oncogene Pok emon in cell ular tran sformation and  
ARF repres sion. Nature,  2005. 433: p. 278 -285. 
55. Hedvat, C.V., et al., Application of tissue microa rray techn ology to the  study of Non - 
Hodgkins and Hodgkin's  Lymphoma.  Hum Pathol, 2002. 33: p. [ADDRESS_144731], 2000. 92: p. 
205-216. 
57. Numico, G.  and M. Me rlano, Secon d-line treatment with do cetaxel after failure of 
Memo rial Sloan-Kettering Cancer Center  
IRB Protocol  
IRB#: 09-131 A(15) 
Amended: 04/22/15  
- 49 -  
  
platinum -based chemot herapy in sq uamous -cell head and neck cancer. Ann Oncol, 2002.  
13: p. 331 -333. 
58. Merlano,  M., et al.,  Ineffectiveness of 5-fluorouracil  and ci s-platin as s econd line  therapy 
in head and  neck canc er. Tumori, 1984. 70: p. [ADDRESS_144732] 
Appendix B - SAE FAX  COV ER SHEET 